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Abstract
Neurological disorders have multiple etiologies such as genetics and age. Stress related disorders
are becoming more common and diagnosed more often. Mental health disorders are no longer
being treated as purely psychological. Mechanisms into the underlying factors of these disorders
continue to bring this area to new frontiers. Chapter 2 of this dissertation focuses on the efforts
made to prove the association of the protein FKBP51 to the stress response. We synthesized and
used a molecular tool to discover and prove these interactions.
The study of neurodegenerative diseases is of continued importance as the world reaches record
numbers of an aging population. Neurodegenerative diseases predominate in Western countries
and it is hypothesized that cultural and socioeconomic factors are involved. Treatments for
neurodegenerative diseases are ineffective and there is a need for new drug discovery research
into these areas. Chapter 3 of this dissertation focuses on efforts in making new analogs of a
known Hsp70 inhibitor, JG-98. This compound is known to clear tau from neurons but is not
particularly blood-brain-barrier permeable. Our research efforts focused on optimizing these two
factors toward more effective compounds against tauopathies.
Infectious diseases are a major cause of human death and suffering worldwide. This is especially
the case in developing countries with limited access to health care and proper sanitation. Current
treatments for infectious diseases are often toxic or expensive. Chapter 4 of this dissertation is
related to infectious diseases and our efforts in making an analog of a known drug, pentamidine.
Pentamidine is used as a treatment for multiple infectious diseases but carries toxic side effects.
x

Our research focuses on making changes to pentamidine to improve its properties with
bioavailability. We further hope this new compound has an improved toxicity profile over
pentamidine.

xi

Chapter 1
Introduction
1.1 Overview of Neurological Disorders and Diseases
Neurological disorders and diseases affect the brain and can be mental health related,
neurodegenerative, or infectious in nature.1 Genetics and age play large roles in neurological
disorders, as do physiological, sociocultural, and environmental factors. The brain is the least
understood organ and decades of neurological disease research has only scratched the surface of
the field.2 The United States has seen increases in neurological disorders and diseases, owing
partly to an increasingly aging population and to an ever increasingly stressful and fast-paced
world.3 These diseases decrease the quality of life not only for individuals, but also for
caregivers. Neurological disorders contributed to over 16% of deaths worldwide in 2016 and
were the second leading cause of death that year.4 The primary diseases in this figure include
tetanus, meningitis, stroke, brain cancer, brain and spinal cord injuries, neurodegenerative
diseases, and headaches.4 It is a worldwide public health challenge to prepare for disorders and
disabilities associated with aging populations.
1.1.1 Mental health disorders
Mental health disorders are illnesses related to anxiety and panic, depression and mood, eating
behaviors, personality, post-traumatic events, and psychosis.5 Mental health illnesses can be
temporary or chronic and can affect the daily quality of life of an individual. Genetics, chemical
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imbalances, substance abuse, and underlying inflammatory diseases or injuries are some of the
factors leading to mental illnesses.5 Less-defined aspects like life experiences are also important
causative factors.
Mental illnesses are often overlooked as a public health concern, despite over half of Americans
being diagnosed with a mental illness at some point in their life.6-7 Suicide is the second leading
cause of death for youth ages 10 to 19.8 Underdiagnosed mental health crises and limited access
to mental health care have led to an increase of deaths by suicide. Trends to increase awareness
and decrease stigma with mental health have led to increased rates of seeking care. In 2015, there
were over 40 million American adults with a mental illness and nearly 10 million adults with a
serious mental illness.7-8 A serious mental illness is defined as one which interferes with major
life activities.7 Mood disorders are the third major cause of hospitalization in adults under 45.
Adults with serious mental illnesses live 25 years fewer than others.7 These brief statistics
highlight the importance in promoting mental health awareness to improve quality of life. It is
equally important to expand research behind the causes of such mental health disorders, as well
as research on new treatments.
1.1.2 Anxiety
Anxiety disorders are associated with responses of fear and terror to particular situations. These
disorders include generalized anxiety, social anxiety, panic disorders, and phobias.9 Anxiety
disorders are considered symptoms beyond temporary worry and fear; these symptoms are
simply an aspect of life.7 Generalized anxiety disorder is an excessive worry on most days for at
least a six-month period.6,

9

Prolonged anxiety leads to development of physical symptoms,

including muscle tension, headaches, rapid heartbeat, shaking, trouble sleeping, and fatigue.9
Additionally, emotional symptoms include panic, difficulty concentrating, anger, and
2

restlessness.9 Panic disorders are conditions causing moments of uncontrollable fear known as
panic attacks, which mimic the symptoms of a heart attack like palpitations and chest pain.9
Social anxiety disorder is associated with fearful feelings of interacting with others.
Psychotherapy and medications are the two ways anxiety disorders are treated, provided either
alone or in combination. A therapist can help a person learn how to think and react differently to
anxiety-inducing situations. Medications for anxiety do not cure the disorder and only help
relieve symptoms.9
1.1.3 Depression and mood disorders
The main types of mood disorders are depression and bipolar disorder.6 Depression is the most
prevalent psychiatric disorder and is associated with negative moods impacting a person’s daily
physical and psychological well-being.10 Persistent feelings of sadness lead to a loss of interest in
activities and can cause problems in a person’s ability to work.7 Depression symptoms also
involve changes in appetite, sleep habits, energy levels, and ability to concentrate. The American
Psychiatric Association states that symptoms must be present for two weeks for depression to be
diagnosed in an individual.10 Depression differs from the difficulties experienced during grief or
bereavement; sadness and grief are natural feelings after a loss. Depression is considered a
neurologic disorder and not just a psychiatric disorder.1, 11 Neuroimaging studies reveal atrophy
in the hippocampus and frontal lobe in patients with major depressive disorder.1
Depression is among the most treatable of mental illnesses. Altered chemicals in the brain due to
depression can be treated with antidepressant medications. One of the drawbacks of these
medications is that they may take months to work properly.10 Like anxiety disorders,
psychotherapy is another common treatment given in combination to medication. Extreme cases
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of depression can be treated with electroconvulsive therapy, in which the brain is electrically
stimulated.
1.1.3 PTSD
Traumatic events such as war, natural disasters, physical abuse, violence, and accidents are the
main causes of posttraumatic stress disorder (PTSD).12 It encompasses symptoms like reliving
traumatic events and causing distress and changes in emotions and behavior.9 PTSD causes fear
and stress long after the event occurred. A PTSD diagnosis requires that re-experiencing
symptoms (e.g. flashbacks or frightening thoughts) or avoidance symptoms last one month.9, 12
Treatments for PTSD consist of psychotherapy and medications for anxiety and/or depression.
Untreated PTSD can leave a person impaired from daily life activities. Psychotherapy used in
PTSD primarily involves exposure therapy, which involves slow exposure to fear-causing
situations.12
1.1.4 Current treatments and limitations
Treatments for these three disorders overlap, and there is no one treatment for each patient. The
most commonly prescribed medications for anxiety disorders consist of anti-anxiety medications,
antidepressants, and beta-blockers.6-7 Benzodiazepines are the most common of the anti-anxiety
drugs due to their effectiveness.9 However, the main drawback is that they can lead to tolerance
and dependence. These drugs require a slow and gradual reduction because suddenly stopping
can cause severe withdrawal symptoms. Antidepressant medications may not be effective for
every patient.10 Additionally, antidepressants may take months before a conclusion can be
reached about effectiveness.10 Selective serotonin reuptake inhibitors and serotonin reuptake
inhibitors are antidepressants used as first-line treatments for anxiety.9 An important note is that
4

antidepressant medications can increase suicidal thoughts in patients taking them. Beta-blockers
are drugs typically used to treat high blood pressure; these help with the physical symptoms of
anxiety.7, 13
1.2 Neurodegenerative Diseases
Neurodegenerative diseases are a set of diseases that cause breakdown of neurons and brain
matter; these lead to progressive loss of structure and function and a declination of overall
health.14 The loss of neurons may be due to genetics, injury, or environmental factors.3,

14

Neurodegenerative diseases generally consist of misfolded proteins that deposit in the brain and
disrupt homeostasis.15 Dementia is defined as a syndrome characterized by cognitive impairment
and a deterioration of memory, behavior, and motor functions.16 Alzheimer’s disease,
Parkinson’s disease, and Huntington’s disease are common examples of neurodegenerative
diseases. The main risk factor for dementia is age; onset before age 65 is uncommon, but the risk
doubles every five years past age 65.17-18 Dementia is considered a progressive and irreversible
disease.18
1.2.1 Alzheimer’s disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common form
of dementia in people over 65 years of age.18 It was first described in 1906 by Alois Alzheimer
and since then, continuous efforts have been made to find a cause and cure for this disease.
Alzheimer first reported a patient with severe memory loss and behavioral changes; an analysis
of the patient’s brain postmortem revealed extreme shrinkage and the presence of extracellular
plaques and neurofibrillary tangles (NFT) inside cells.19
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Alzheimer’s disease is not considered a normal part of aging. Dementia currently affects over 35
million people worldwide and there are an estimated 5.8 million Americans living with AD.16, 20
It is the sixth leading cause of death in the United States.18 Current diagnostics state that AD may
begin years before any symptoms appear, so more people may have AD than what is currently
known. Similarly, patients may be diagnosed with AD dementia, but some autopsy studies
indicate that up to 30% of individuals did not have classic AD changes in the brain, thus were
misdiagnosed.4,

18

Further research is needed to develop biomarker detection to accurately

identify AD in the pre-symptom stages.
AD can be divided into early, middle, and late stage in terms of symptoms. The early stage is
underdiagnosed and dismissed as simply “old age”. Symptoms in the early stage include
language problems, memory loss related to new information, mild disorientation, inactivity,
depression and mood changes, difficulty with decision-making, and a loss of interest in
activities.16,

18-19

Middle stage symptoms show significant disease progression. These include

difficulty with daily tasks, moderate memory loss, speech difficulties, wandering, disturbed
sleeping, disorientation in familiar places, and hallucinations.16,

19

The late stage of AD is

serious, and patients are fully dependent on caregivers. Problems in this stage involve inability to
recognize family or friends, difficulty understanding and communicating with others,
incontinence, and inability to eat or walk.16,

18

The symptoms encompass the near-complete

deterioration of behavioral, cognitive, and motor functions.17
1.2.2 Etiology
There are two main hallmarks in Alzheimer's disease. The first is the accumulation of
extracellular plaques of amyloid-beta (Aβ) peptides.14 The other hallmark is the accumulation of
intracellular neurofibrillary tangles made up of hyperphosphorylated tau.14, 19 Together, plaques
6

and tangles cause cell communication problems between neurons at synapses and eventually
block the proper transport of nutrients to neurons. Multiple hypotheses over the last decades have
been developed for the cause of AD. For example, the mitochondrial cascade hypothesis
suggests that mitochondrial baseline function and durability depends on inheritance.14 Over time,
oxidative damage to mitochondrial components leads to reduced metabolic activity of energyrelated proteins such as pyruvate dehydrogenase.14
The senile plaques found in between neurons are made up of 40-42 amino acid peptides known
as amyloid-beta.19 These peptides are derived from cleavage of the Aβ precursor protein (APP)
by β-secretase followed by γ-secretase cleavage.19 Aβ peptides are hydrophobic and thus they
cluster and self-aggregate.19 This leads to the formation of insoluble plaques. In a small number
of AD cases, genetic mutations in the coding for γ-secretase and APP demonstrate increased Aβ
production.19 Aβ plaques can be detected through the use positron emission tomography (PET)
scans. Carbon-11 Pittsburg compound B (11C-PIB) binds to amyloid plaques quickly upon
entering the body and are then detected through a PET scan.16 Although this is one way that AD
can be detected, the formation of Aβ plaques indicates the disease has progressed significantly.
Neurofibrillary tangles are made up of aggregates of tau protein. Tau is encoded by the MAPT
(microtubule associated protein tau) gene, which contains 15 exons.19 Alternative splicing of
exons produces the six major isoforms of tau.19 Tau is highly present in neurons and other cells
such as oligodendrocytes.21 Tau affects neuron signaling, development, and survival through its
interactions with other proteins. Most tau proteins are located on the microtubules within the
axon of a neuron, where they help regulate transport across the axon.21 Dissociation of tau from
microtubules causes destabilization of the microtubules.22 The destabilization of axons and the
blocked nerve synapses by NFT together cause neuron death.22
7

Research on AD focuses on Aβ and tau pathology. Transgenic mouse models focusing on these
two proteins are used to understand the etiology of AD. No mutations have been identified in the
MAPT gene in AD cases, but mutations in this gene are found in other neurodegenerative
diseases such as frontotemporal dementia.19 The expression of human P301L tau in mice
produces tau aggregation and the formation of NFT, so this model is used successfully in AD
research.19
1.2.3 Current treatments

Figure 1.1 Treatments for Alzheimer’s Disease
Treatments for Alzheimer’s disease only help with the symptoms, but do not cure the disease or
change the underlying disease processes. Current approaches to AD treatment focus on slowing
symptom progression of the disease and work best in the early and middle stages of AD.23
Cholinesterase inhibitors are the medications used for the earlier stages.23 These include
donepezil, rivastigmine, and galantamine (Figure 1.1). Cholinesterase inhibitors prevent the
breakdown of acetylcholine, a neurotransmitter important to memory and motor functions.20, 23
However, in the progression of AD, less acetylcholine is produced, so these treatments
eventually have a reduced effect.20,

23

Moderate to severe AD is treated with memantine or a
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combination of memantine and donepezil. Memantine is an N-methyl

D-aspartate

antagonist

used to block the effects of excess glutamate. Additional medicines used for depression and
anxiety may be given to patients to manage behavioral symptoms.
1.3 Blood-Brain Barrier
Drug discovery for neurological disorders must take the blood-brain barrier into consideration.
The blood-brain barrier (BBB) is a cellular system of endothelial cells that separates the brain
from blood circulation.24 It was discovered by Paul Ehrlich in 1885 when he observed that a dye
stained animal organs but not brain tissue.24 The BBB exists to protect the central nervous
system (CNS) from harmful substances and metabolites and to regulate transport of essential
nutrients. Capillary endothelial cells, astrocytes, microglia, and pericytes form the neurovascular
unit.24 Effective treatment of CNS diseases such as depression and Alzheimer’s disease requires
that the therapeutic compounds cross the BBB to enter the site of disease.25
The BBB is formed by tight junctions of endothelial cells of brain capillaries. About 98% of
small molecule drugs and all large drugs are excluded from entering the brain. 24 The movement
of nutrients and large, polar molecules requires transport proteins at the membrane.24-25 Cell
membranes allow for lipophilic molecules to pass through due to the internal lipid nature of the
membrane. Many drugs entering the CNS are lipophilic, although lipophilicity does not
necessarily correlate to BBB permeability.25 Endothelial cells interact with other brain cells for
the proper maintenance of the BBB. Endothelial cells are surrounded by pericytes, and research
suggests pericytes cover 30-70% of the capillary wall.24 These cells contain lysosomes that
degrade macromolecular compounds. Astrocytes enhance BBB properties by expressing tight
junction proteins and reducing permeability across the endothelium.24 BBB dysfunction is
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implicated in CNS diseases such as AD and Parkinson’s disease, as well as HIV infection,
tumors, and sepsis.26
Overcoming the BBB remains a challenge for CNS drug discovery. Dosing a drug candidate into
an organism is not possible without prior efficacy studies. Models to test BBB permeability have
been developed using cerebral cells and/or artificial membranes.27 Models that mimic a living
system are the most accurate, though more costly. The use of artificial membranes is a more
cost-effective way to test BBB permeability. It is important to keep in mind that physicochemical
properties alone cannot model the cells in the BBB accurately due to the lack of transport
proteins.27 The compounds made in Chapter 3 of this manuscript were tested for BBB
permeability through a Parallel Artificial Membrane Permeability Assay (PAMPA) as a costeffective way to guide the creation of new analogs.
1.4 Infectious Diseases
Infectious diseases are illnesses caused by organisms such as bacteria, viruses, protozoa, or
fungi. Communicable diseases are a major cause of death worldwide and are considered a threat
to human health due to rapid spread from person to person.28 Infectious diseases are commonly
found in developing regions of the world, especially in areas with poor sanitation and lack of
clean water. Globalization is another factor that contributes to the spreading of infectious
diseases across continents; this is especially important as the world grows more interconnected
and international travel becomes easier.29 Increasing world population centered around urban
areas further complicates limiting the spread of contagious diseases.30
Scientists, doctors, and researchers have developed ways to help combat infectious diseases.
Antibiotics were developed to help fight bacterial infections. Vaccines have helped eradicate
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deadly diseases of the past such as smallpox; polio has reached near-eradication worldwide due
to successful vaccination campaigns. Some diseases such as measles are unfortunately making a
comeback in developed countries due to misinformation campaigns that lead to lower
vaccination rates.31 Nevertheless, not every disease can have a vaccine available, and the process
of making effective prophylaxis can take many years. Generally, treatments for common
infectious diseases are available in developed countries, but the developing world still has a lack
of widely available and cost-effective treatments. Increasing resistance to currently available
treatments poses additional problems to global public health.29
1.4.1 Neglected tropical diseases
Certain infectious diseases receive widespread attention and funding to help combat or eradicate
them. These diseases include HIV, malaria, and tuberculosis. The World Health Organization has
classified certain diseases as Neglected Tropical Diseases (NTD) due to little attention and
funding, and a general lack of effective treatments.32 NTDs predominate in warm regions of the
world centered around the tropics, where infectious microorganisms thrive, and insects are
common carriers of disease. Climate change is an additional factor that drives diseases to these
areas through extreme weather events and changes in temperature and rainfall.30
NTDs are present in 149 countries around the world and affect over one billion people.32 The
World Health Organization has named twenty such diseases a priority, including: leishmaniasis,
human African trypanosomiasis (African sleeping sickness), onchocerciasis (African river
blindness), dengue and Chikungunya, and Chagas disease.32 Developing countries are the
primary locations of these diseases, thus the people most affected are often in the world’s most
impoverished regions. Remote locations within these countries limit access to treatments that
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require special handling and hospitalization. The lack of profitability for new medicines against
NTDs further hinders efforts to gather corporate interest in developing new drugs.
1.4.2 Leishmaniasis

Figure 1.2 Global Endemicity of Cutaneous Leishmaniasis33
Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania and spread by
the female sandfly. It is one of the NTDs classified by the World Health Organization and it is
the 9th greatest global disease burden. Leishmaniasis is found in 98 countries and 350 million
people are at risk.33-34 Figure 1.2 shows a map of cutaneous leishmaniasis cases worldwide based
on statistics by the World Health Organization.33 It is estimated that 12 to 15 million people are
infected and there are about 2 million new cases every year.34 It is found primarily in tropical and
subtropical Africa, Asia, and South America.32, 35 People most affected by this disease are often
impoverished and suffering from malnutrition. Malaria is the only parasitic disease with a higher
mortality than leishmaniasis.
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There are over 20 species of Leishmania known to infect humans.34 There are three main types
of leishmaniasis: visceral (also known as kala-azar), cutaneous, and mucocutaneous. Visceral
leishmaniasis is the deadliest type and causes symptoms such as: fever, weight loss, internal
organ enlargement, and anemia.34 This type has a greater than 95% mortality rate within two
years if left untreated.36 Cutaneous leishmaniasis is the most common form and causes skin
lesions at the site of the insect bite. Mucocutaneous leishmaniasis affects the mucous membranes
and causes facial disfigurement; this occurs after the appearance of cutaneous leishmaniasis in
some patients. Skin lesions caused by cutaneous and mucocutaneous leishmaniasis can lead to
bacterial infections if left untreated.36
Leishmania parasites have two stages in their lifecycle. The human stage starts when a female
sandfly takes a bloodmeal and the parasite enters the bloodstream.37 In this stage, the parasite is
in the form of a flagellated promastigote and is phagocytosed by macrophages. Inside
macrophages, the parasites transform into amastigotes. These multiply inside human cells and
cause further infection to other cells. The cycle returns to the sandfly stage when a sandfly takes
a bloodmeal from an infected human. The amastigotes transform into promastigotes in the gut of
the sandfly.37
Current treatments for leishmaniasis have specific drawbacks such as toxicity, side effects, high
cost, or special administration. Pentavalent antimonials such as sodium stibogluconate and
meglumine antimonate are frequently used drugs to treat leishmaniasis despite limited
effectiveness.36, 38 Additionally, antimony-based drugs can have severe toxicity problems such as
cardiac arrythmia. Amphotericin B is the most effective treatment; however, treatment can cost
thousands of dollars and is therefore cost prohibitive to most of those affected.36 It also requires
liposomal administration, and often requires hospitalization, further making this an inconvenient
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treatment option.36, 38 Miltefosine is the only orally available drug to treat leishmaniasis but has
severe side effects including hepatic toxicity, teratogenicity, and high cost.36 Paromomycin is an
aminoglycoside antibiotic with high efficacy against certain strains, but it requires parenteral
administration.36 Pentamidine is another drug commonly used as treatment. Its main drawbacks
are high toxicity, poor oral bioavailability, and the emergence of resistance by certain
Leishmania strains.36, 38 Due to most treatments having major drawbacks, there is a global need
for new medicines to combat leishmaniasis.
1.4.3 Trypanosomiasis, “African sleeping sickness”
Human African trypanosomiasis, also known as sleeping sickness, is a parasitic disease spread
by the tsetse fly infected with protozoa of the genus Trypanosoma. This disease is primarily
found in rural regions of sub-Saharan Africa, often in areas with inadequate health services.35
Sleeping sickness is not necessarily found everywhere tsetse flies are found. Signs and symptoms
manifest as pain, fever, headaches, and joint weakness in the first stage of the disease. The
parasite can cross the blood-brain barrier, where it can cause damage to the central nervous
system in the second stage.32, 35 Illness may be either acute, with central nervous system changes
developing rapidly, or chronic, bypassing signs and symptoms for years.35 This disease causes
physical and mental disabilities; in children, growth and development are impaired. A similar
form of this disease, known as Chagas disease, is found in Latin America and is caused by
Trypanosoma cruzi.29
Current treatments for trypanosomiasis include pentamidine for the first stage of T. b. gambiense
infection and suramin to treat T. b. rhodesiense infection.35 Melarsoprol is used as a second stage
treatment for both forms of this disease; however, melarsoprol can have fatal toxic side effects. 35
A combination therapy of eflornithine and nifurtimox has proven effective in treating patients
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with trypanosomiasis.32 Although medicines are provided by WHO through public-private
partnerships, the cost of eflornithine production and administration is high and new treatments
are still needed to fight the first stages of trypanosomiasis. Early detection is also crucial since
the second stage of the disease requires hospitalization and can cause permanent neurological
damage.
1.4.4 Naegleria fowleri, the brain-eating amoeba
Naegleria fowleri is a parasite living in or near freshwater in warm regions, such as lakes, ponds,
hot springs, soils, and in unchlorinated pools. It can cause a sudden and severe brain infection
known as naegleriasis or primary amoebic meningoencephalitis (PAM).39 Although this is not
classified as a neglected tropical disease, it is a fatal parasitic disease affecting the central
nervous system for which there is no current effective treatment.39-40 Infection starts by the
inhalation of contaminated water. The parasite travels through the nasal mucosa and eventually
to the olfactory nerve and the brain, where it causes severe damage and leads to death within a
week.39 N. fowleri digests brain matter and releases enzymes and molecules that facilitate the
destruction of nervous tissue.39
This disease itself is rare in the United States, with only 138 infections in over half a century.41
The primary treatment is Amphotericin B. As described previously, Amphotericin B is an
effective treatment for certain parasitic diseases, but its high cost and complicated administration
increases the need for other options. The fatality rate with Amphotericin B treatment is still
greater than 95%.40 Signs and symptoms are like those of bacterial meningitis; these include
headache, fever, stiff neck, seizures, altered mental status, and coma. Recent research has
demonstrated potency of pentamidine and other diamidines against free-living amoeba such as N.
fowleri.40
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1.4.5 New directions in treatments
Infectious diseases are rapidly becoming resistant to current treatments. These diseases are major
causes of morbidity and mortality in tropical and subtropical countries. It is imperative to seek
new sources of antibiotic, antifungal, and antiprotozoal drugs to find novel ways to combat these
diseases. Every so often, new treatments are derived from nature itself. The isolation of natural
products can help us understand the ways microorganisms fight each other. New drugs also come
from modifications of existing drugs to work around known resistance mechanisms in
microorganisms.
The three aforementioned diseases have one thing in common: pentamidine is used as a
treatment in some regions of the world. Pentamidine isn’t an ideal drug due to its toxicity and
lack of oral bioavailability. Despite its simple structure, pentamidine is active against multiple
parasitic diseases to some extent. We believe this makes pentamidine an ideal candidate for
modification to improve upon its properties.
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Chapter 2
Use of a Chemical Probe for FKBP51-Related Stress Disorders
2.1 The Stress Response and FKBP51
Stress is regulated through the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is a
critical part of the neuroendocrine system and controls functions including the immune response,
digestion, metabolism, and the stress response.1 The HPA axis is regulated by glucocorticoid
hormones (CORTs) produced by the adrenal cortex.1-2 Following a stressor, the hypothalamus
releases corticotropin releasing hormone (Figure 2.1). This activates the pituitary gland to release
adrenocorticotropic hormone (ACTH) to act on the adrenal cortex.1 The adrenal cortex then
releases CORT, which in turn binds to glucocorticoid receptors (GR) in the brain. GR are highly
expressed in the hippocampus, amygdala, and hypothalamus. The binding of CORT to GR leads
to an inhibition of ACTH production to restore CORT levels.1,

3

The 51kDa FK506 binding

protein (FKBP51) is expressed in the brain and helps regulate the stress response system.3 It acts
as a co-chaperone to 90 kDa heat shock protein (Hsp90). FKBP51 and Hsp90 together suppress
GR activity by reducing the affinity of CORT to the receptors.4-6 When bound to CORT, the
receptor enters the nucleus and leads to an upregulation of FKBP5, which encodes for FKBP51,
making a negative feedback loop.3 Higher levels of FKBP51 extend the duration of the stress
response by allowing increased levels of CORT in circulation.7
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Figure 2.1 The HPA Axis
Imbalances in HPA axis signaling is observed in people with psychiatric disorders.1, 8 Patients
with major depressive disorder have elevated CORT in circulation and CORT resistance.7 In
general, patients with anxiety and depression exhibit HPA hyperactivity likely due to persistent
CORT in the limbic system.6,

9

Patients with PTSD exhibit the opposite, HPA hypoactivity,

where prolonged stress likely causes a desensitization of the HPA axis.6 FKBP51 is implicated in
these psychiatric disorders in addition to other diseases such as Alzheimer’s disease and
cancer.10-12 Studies suggest that higher levels of FKBP5 produced by single nucleotide
polymorphisms (SNPs) combined with environmental factors allow for higher levels of FKBP51
to be made following stress.7,
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FKBP5-knockout mice are viable and present anti-depressive

phenotypes and improved stress responses.14-17 Higher levels of FKBP51 lead to detrimental
effects, therefore decreasing levels or activity of FKBP51 may have therapeutic benefits on
patients with psychiatric disorders.3, 7, 18
2.2 Small Molecules to Disrupt Complex
A high-throughput assay using the LOPAC library was done by Dr. Chad Dickey’s lab to
identify compounds that could block FKBP51 suppression of GR activity.3 Graph 2.1 (top)
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shows how four compounds in this library were found to increase GR activity in the presence of
FKBP51: 3-aminobenzamide (3-AB), (E)-5-(bromovinyl)-2′-deoxyuridine (BVdU), benztropine,
and resveratrol (Figure 2.2).3 As shown in Graph 2.1 (bottom), BVdU increases GR activity
independent of FKBP51, whereas the others are dependent on FKBP51.

Graph 2.1 Four Compounds Increase GR Activity Indicated by Luciferase Activity3
(Top) Quantification of luciferase activity following LOPAC library screen.
Chemiluminescence was normalized within each plate and converted to Z scores.
Four compounds significantly increased GR activity: 3-aminobenzamide (3-AB;
green), (E)-5-(bromovinyl)-2′-deoxyuridine (BVdU; orange), benztropine (blue),
and resveratrol (red). (Bottom) Quantification of luciferase activity in HeLa cells
transfected with a glucocorticoid response element (GRE) luciferase reporter and
treated with hormone and indicated drugs. ***p < 0.001 by one-way ANOVA.
Rel = relative.
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Figure 2.2 Compounds Found to Increase GR Activity
An in vitro flow cytometry assay was done next to validate the disruption of the
FKBP51/GR/Hsp90 complex. A biotinylated recombinant GR bound to streptavidin beads was
incubated with recombinant Hsp90 and fluorescently labeled FKBP51 and incubated with either
3-AB, benztropine, or resveratrol. This study revealed that benztropine mesylate was the only
compound that disrupted the FKBP51/GR/Hsp90 complex in vitro, as measured by fluorescence
(Graph 2.2, top).3 Further analyses with a neuroblastoma cell line confirmed the effects of
benztropine increasing GR activity in the presence of FKBP51 (Graph 2.2, bottom).3 Overall,
these tests showed that it was possible to disrupt FKBP51 signaling with a small molecule. The
next step was to test whether benztropine was binding to FKBP51 as part of its complexdisrupting effects.
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Graph 2.2 Effect of Benztropine Disrupting the FKBP51/GR/Hsp90 Complex3
(Top) Median bead-associated fluorescence was measured for each compound at
the indicated range of doses. (Bottom) GR activity was measured by luciferase
assay in M17 cells treated as shown. *p < 0.05 by one-way ANOVA.
2.3 Design and Synthesis of Probe
In order to test if benztropine increased GR activity through binding interactions with the
FKBP/GR/Hsp90 complex, we sought to use a probe molecule containing benztropine. We
hypothesized that benztropine was binding to FKBP51, so to prove this, the probe was designed
with biotin attached to a modified version of benztropine through a linker. Biotin is widely used
in protein binding assays due to its strong binding to streptavidin beads; anything bound to the
biotin linked probe is removed from media along with the beads. We also needed to maintain the
tertiary amine properties of benztropine. In order to keep maximum similarity to benztropine, we
chose 2.01 (Figure 2.3) as our desired probe. Compound 2.01 contains all the functionality of
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benztropine and can be linked to a commercially available biotin with a polyethylene glycol
(PEG) linker. We decided to use Barry Sharpless’ successfully developed copper catalyzed [3+2]
azide-alkyne cycloaddition reactions, commonly known as click chemistry.19 We first
synthesized the corresponding analog of benztropine, in which the nitrogen contains a propargyl
chain to be connected to a biotinylated azide.

Figure 2.3 Structure of Molecular Probe
We started the synthesis from commercially available tropine (2.02) as shown in Scheme 2.1.
Tropine was first alkylated with benzhydryl chloride to obtain benztropine hydrochloride, which
was converted to the free tertiary amine under basic conditions to obtain benztropine (2.03).19
The amine in 2.03 was then demethylated with chloroethyl chloroformate to get the free
secondary amine. Unfortunately, the workup and column chromatography conditions using
methanol consistently led to the formation of the methyl carbamate 2.04. The secondary amine
was generated using harsher conditions of potassium hydroxide heated in ethanol.20 The use of
methanol in a column to purify the secondary amine might have led to the methyl carbamate
being formed again, so ultimately, the next step was done without further purification of this
reaction. The crude secondary amine was deprotonated with sodium hydride and alkylated with
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propargyl bromide to generate the tertiary amine 2.05 containing the desired alkyne for a click
reaction.21

Scheme 2.1 Synthesis of Biotinylated Benztropine
Finally, 2.05 was reacted with a commercially available azide PEG3 biotin conjugate, and the
standard click reagents of copper (II) sulfate and sodium ascorbate to obtain the final product
2.01 with an excellent yield.22
2.4 Results of the Benztropine Molecular Tool
Our molecular probe was tested for its ability to bind to FKBP51. Fluorescently labeled
FKBP51, FKBP52 (a homologue of FKBP51), and BSA were incubated with streptavidin beads
in the presence or absence of the biotinylated benztropine probe. The benztropine probe
interacted with FKBP51 as hypothesized but did not interact with FKBP52 or BSA. Graph 2.3
shows the quantification of median fluorescence intensity indicating binding activity to
FKBP51.3
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Graph 2.3 Binding of Benztropine Probe to FKBP513
Quantification of the median fluorescence intensity. FCPIA = flow cytometry
protein interaction assay; *Benz = biotinylated benztropine; Protein = BSA,
FKBP51, and FKBP52. n.s. = not significant, *p < 0.05 by one-way ANOVA.
Benztropine interacted directly with FKBP51 to remove it from the Hsp90/GR complex and did
not directly increase GR activity. The presence and absence of benztropine and CORT were
tested for their effects on the interactions between FKBP51 and GR. It was found that the
presence of both the hormone and benztropine decrease the amount of FKBP51 bound to the
Hsp90/GR complex (Figure 2.4). The quantification of the Western blot is indicated by the
graph. This study concluded that benztropine is more effective at inhibiting the
FKBP51/GR/Hsp90 complex in the presence of CORT and both have a synergistic effect of
increasing GR activity.
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Figure 2.4 Hormone Dependent Disruption of FKBP51/GR/Hsp90 Complex3
(Top) HeLa cells were transfected with FKBP51 and treated with the indicated
doses of the hormone hydrocortisone (CORT) and/or benztropine prior to
immunoprecipitation of GR and Western blotting. (Bottom) Quantification of the
Western blot is shown. *p < 0.05 by one-way ANOVA.
Benztropine is an antagonist of muscarinic acetylcholine receptors, histamine receptors, and
dopamine transporters. Other compounds from the LOPAC library that target these receptors did
not inhibit FKBP51 or lead to an increase in GR activity. Similarly, compounds structurally
similar to benztropine were tested for their ability to increase GR activity and it was found that
only benztropine is effective (Figure 2.5). This suggested that benztropine is acting through a
different mechanism not involving these other receptors.
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Graph 2.4 GR Activity of Benztropine and Other Muscarinic Antagonists3
HeLa cells were transfected with GRE luciferase and FKBP51 or 6TR. Cells were
treated with benztropine, biperiden, brompheniramine, atropine, or
diphenhydramine as well as a hormone. GR activity was measured using a
luciferase assay. ***p < 0.01, n.s. = not significant by one-way ANOVA.

Figure 2.5 Structure of Benztropine and Other Muscarinic Antagonists
2.5 Discussion
The wide functional group tolerability of copper (II) catalysts is one of the greatest aspects of
click chemistry. 1,2,3-Triazoles can be synthesized with great yields at a late-stage in a synthesis
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with little worry that side reactions will occur. Click reactions occur without elimination of
byproducts and with high conversion to product. Additionally, the use of aqueous solvents for
click reactions reduces the need for large quantities of organic solvents and allows for use
directly in biological settings.23 In the words of Barry Sharpless, “the process is experimentally
simple;” reactions occur at room temperature, with a wide variety of solvents, and without care
for having an inert atmosphere.19 Our synthesis for the benztropine molecular tool was plagued
with a step with consistent poor yields. Although only a small amount of the propargyl analog of
benztropine was isolated, the proceeding click reaction made good use of our small quantities of
starting materials.
Benztropine mesylate was identified as a highly specific FKBP51 inhibitor. Benztropine binds to
FKBP51 and disrupts the FKBP51/GR/Hsp90 complex, leading to an increase in GR activity.
The presence of glucocorticoid hormones increased the FKBP51-disrupting effect of
benztropine. These results suggest it is possible to inhibit a steroid hormone receptor inhibitor
with a small molecule. Finding a specific inhibitor of FKBP51 is essential since its homologue,
FKBP52, has critical developmental and neuroendocrine functions. The molecular tool used in
these studies can improve further research to find new therapeutic compounds in FKBP51related stress disorders.
2.6 Experimental Procedures
All reagents and solvents, unless specifically stated, were used as obtained from commercial
suppliers without further purification. Air and moisture sensitive reactions were performed under
an inert atmosphere using argon in a previously oven-dried reaction flask, and addition of
reagents was done using a syringe. Dry tetrahydrofuran (THF) was obtained via distillation from
sodium benzophenone ketyl. All microwave (mW) reactions were carried out with an Anton Paar
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Monowave 300 instrument. Thin layer chromatography (TLC) analyses were performed using
200 µm pre-coated Sorbtech fluorescent TLC plates. Plates were visualized by UV light and by
staining with different stains including iodine vapor, ceric ammonium molybdate, acidic vanillin,
or acidic anisaldehyde. Analytical LC/MS data was obtained using an Agilent 1100 HPLC/MSD
system equipped with a diode array detector running an acetonitrile/water gradient and 0.1%
formic acid. Purification of compounds was carried out using Sorbtech silica gel (60Å porosity,
40-63 µm particle size) in fritted MPLC cartridges and eluted with Thomson Instrument
SINGLE StEP pumps. Reverse phase preparative HPLC (prep HPLC) purification was achieved
on an Agilent preparative 1200 LC/6120B single quadrupole mass spectrometer.
High resolution mass spectral (HRMS) data was acquired on Agilent 6540 Ultra-High-Definition
(UHD) liquid chromatography quadrupole time-of-flight mass spectrometer (LC/QToF-MS) with
electrospray ionization (ESI) detection. Nuclear magnetic resonance (NMR) spectrometry was
run on Varian dd 500 MHz, Varian Inova 500 MHz, Varian Inova 400 MHz, Varian Mercury
400 MHz, or Bruker Neo 600 MHz spectrometer and data was processed using ACD/NMR
processor. Chemical shifts are listed in ppm correlated to the solvent used as an internal standard.
All compounds were determined to be >95% pure by HPLC analysis and further confirmed by
NMR analysis.
General synthetic procedures:
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Tropine (2.02, 1.052 g, 7.45 mmol) and benzhydryl chloride (1.4 mL, 7.9 mmol) were added to a
25 mL round bottomed flask containing a stir bar to give a tan solution. The mixture was heated
with stirring to 160 °C for 1 hour, then allowed to cool to room temperature. The residue was
dissolved in dichloromethane and then evaporated to obtain a brown oil. The oil was triturated in
ether to yield a tan solid as the HCl salt of the crude product. Saturated sodium carbonate was
added to this suspension, then the aqueous layer was extracted with ethyl acetate. The combined
organic layers were dried with sodium sulfate and evaporated under reduced pressure to yield
2.03 (2.12 g, 93%) as a light brown oil. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.27 (m, 8 H), 7.24
– 7.16 (m, 2 H), 5.40 (s, 1 H), 3.61 – 3.59 (m, 1 H), 3.17 (br s, 2 H), 2.32 (s, 3 H), 2.21 (br d, J =
7.5 Hz, 2 H), 2.07 – 1.86 (m, 6 H) ppm. LRMS m/z: [M+H]+ = 308.

A solution of 2.03 (4.07 g, 13.2 mmol) in 1,2-dichloroethane (65 mL) was stirred in a 250 mL
round bottomed flask, and sodium carbonate (5.64 g, 53.2 mmol) and 1-chloroethyl
chloroformate (5.78 mL, 53.0 mmol) was added. The mixture was heated with stirring to 85 °C
for 3 h, then cooled and filtered. The filtrate was concentrated on a rotary evaporator, then
dissolved in methanol and stirred at room temperature overnight. This mixture was concentrated
on a rotary evaporator to give an off-white solid that was dissolved in dichloromethane and then
washed twice with 5.5 M ammonium hydroxide and water. The organic layer was then dried
with magnesium sulfate and concentrated on a rotary evaporator to give 2.04 as a brown oil (4.34
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g, 93%) that was used without further purification. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.27
(m, 8 H), 7.25 – 7.17 (m, 2 H), 5.42 (s, 1 H), 4.24 (br s, 2 H), 3.70 – 3.65 (m, 4 H), 2.23 (q, J =
6.3 Hz, 2 H), 2.07 – 1.86 (m, 6 H) ppm. LRMS m/z: [M+H]+ = 352.

A stirred mixture of 2.04 (1.334 g, 3.79 mmol) in 2 M potassium hydroxide (37 mL, 74 mmol)
and ethanol (35 mL) in a 100 mL round bottomed flask was heated to 100 °C for 14 h, then
concentrated on a rotary evaporator and extracted with ether. The combined organic extracts
were washed with water and concentrated on a rotary evaporator to give the crude secondary
amine (1.22 g), which was used without further purification. This residue was taken up in dry
THF (5 mL) and added dropwise to a suspension of 60% sodium hydride (183 mg, 4.57 mmol)
in dry THF (5 mL) at 0 °C under argon. Upon completion of the addition, the mixture was
allowed to warm to room temperature for 10 minutes, and then propargyl bromide (500 µL, 4.64
mmol) was added via syringe and the reaction was allowed to stir at room temperature overnight.
The reaction was quenched with brine, and the mixture was extracted with ethyl acetate. The
combined organic extracts were dried with sodium sulfate, then concentrated on a rotary
evaporator to give a brown oil. Purification by flash column chromatography (85:15
hexanes:ethyl acetate - 90:9:1 ethyl acetate:methanol:ammonium hydroxide) provided unreacted
2.04 (364.3 mg) as well as pure 2.05 (65.7 mg, 7%). 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.26
(m, 8 H), 7.25 – 7.07 (m, 2 H), 5.40 (s, 1 H), 3.59 (br s, 1 H), 3.35 (br s, 2 H), 3.26 – 3.07 (m, 2
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H), 2.28 – 2.15 (m, 3 H), 2.03 – 1.86 (m, 6 H) ppm. 13C NMR (126 MHz, CDCl3) δ 143.0, 128.4,
127.2, 126.8, 80.7, 71.6, 69.3, 58.3, 41.6, 37.6, 36.5, 25.7 ppm. LRMS m/z: [M+H]+ = 332.
HRMS m/z: [M+H]+ Calcd for C23H26NO 332.2014; Found 332,2012.

A solution of 2.05 (49.0 mg, 148 µmol) and azide PEG3 biotin conjugate (85 mg, 190 µmol,
used as obtained from Sigma Aldrich) in water (500 µL) and t-butanol (500 µL) was stirred in a
10 mL round bottomed flask. Sodium ascorbate (6.90 mg, 35 µmol) and copper (II) sulfate
pentahydrate (4.20 mg, 17 µmol) was added (causing the mixture to turn blue), and the reaction
was stirred at room temperature overnight. The mixture was concentrated on a rotary evaporator,
then taken up in water and extracted with dichloromethane. The combined organic extracts were
dried over sodium sulfate, then concentrated on a rotary evaporator. The residue was purified by
flash column chromatography (85% ethyl acetate, 15% of 10% ammonium hydroxide in
methanol solution) to give 2.01 (92 mg, 80%) as a white solid.
1

H NMR (500 MHz, CD3OD) δ 8.08 (s, 1 H), 7.37 (d, J = 7.3 Hz, 4 H), 7.33 – 7.27 (m, 4 H),

7.26 – 7.19 (m, 2 H), 5.53 (s, 1 H), 5.04 – 4.90 (m, 1 H), 4.60 (t, J = 5.0 Hz, 2 H), 4.47 (dd, J =
7.8 Hz, 4.8 Hz, 1 H), 4.28 (dd, J = 7.8 Hz, 4.5 Hz, 1 H), 3.99 (s, 2 H), 3.90 (t, J = 5.0 Hz, 2 H),
3.67 – 3.55 (m, 10 H), 3.51 (t, J = 5.5 Hz, 2 H), 3.36 – 3.33 (m, 3 H), 3.22 – 3.14 (m, 1 H), 2.90
(dd, J = 12.7 Hz, 5.0 Hz, 1 H), 2.68 (d, J=12.8 Hz, 1 H), 2.45 – 2.35 (m, 2 H), 2.19 (br t, J=7.3
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Hz, 4 H), 2.14 – 2.00 (m, 4 H), 1.76 – 1.53 (m, 5 H), 1.48 – 1.37 (m, 2 H) ppm. 13C NMR (126
MHz, CDCl3, mixture of amide rotamers) δ 175.0, 164.6, 142.6, 140.9, 128.0, 127.0, 126.5,
125.5, 80.8, 70.10, 70.08, 69.98, 69.8, 69.1, 68.0, 61.9, 60.2, 59.5, 55.6, 50.1, 48.4, 45.6, 39.6,
38.9, 35.3, 34.5, 31.8, 28.3, 28.1, 25.4, 24.7, 20.6 ppm. LRMS m/z: [M+H]+ = 776. HRMS m/z:
[M+H]+ Calcd for C41H58N7O6S 776.4169; Found 776.4180.
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Chapter 3
Hsp70 Inhibitors as Treatments for Tauopathies
3.1 Tauopathies
Tauopathies are a group of diseases associated with tau protein dysfunction. Alzheimer’s disease
is the most common of neurodegenerative diseases associated with tau pathology.1 Other
diseases include frontotemporal dementia (FTD), progressive supranuclear palsy, Pick’s disease,
and chronic traumatic encephalopathy. FTD is linked to mutations in the MAPT gene.1 Mutations
alter the ratio of the isoforms of tau produced and can have consequences in neuron function.
Research suggests that tau has prion-like properties due to its ability to pass through cells and
propagate aggregation into neurofibrillary tangles.2-4 It has been suggested that pathological tau
spreads to other neurons by the secretion of tau into the extracellular space.3 The mechanism of
this process, however, is not well understood. For example, mice injected with extracts of
autopsied human brains afflicted with tauopathies result in the mice developing abnormal tau
aggregates.1 However, unlike the traditional definition of a prion, tau is not infectious to other
organisms without deliberate introduction of pathological tau.4
3.1.1 Tau aggregation
The primary function of tau is to stabilize microtubules and to promote their polymerization. Tau
is an intrinsically disordered protein and single monomers of tau are soluble.1,

5

Tau contains

numerous serine and threonine residues which are targets of phosphorylation by kinases.1 Certain
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residues are only phosphorylated in brains with AD.6 Tau can become hyperphosphorylated in
pathological conditions, which leads to the formation of aggregates in the form of filaments.6
Tau is normally phosphorylated on two or three residues. In contrast, hyperphosphorylated tau is
at phosphorylated in least 8 residues.6 Phosphorylation induces conformational changes in tau
and therefore affects its interactions with other proteins.5-6 The regions of tau more likely to
aggregate are located on the microtubule-binding repeats. This means that “free tau”, or tau not
attached to microtubules, is the most likely to become pathological and form aggregates.7
3.2 Hsp70 Role in Tau Aggregation
Proteins are made by ribosomes and properly folded by molecular chaperones. Misfolded
proteins are targeted for re-folding or for degradation by these chaperones. Unfolded or
misfolded proteins that escape molecular chaperones can aggregate into soluble oligomers,
which then lead to the formation of NFT.5 The heat-shock protein (Hsp70) family of chaperones
engage with pathological tau, though different Hsp70 variants interact differently.8 Heat-shock
cognate 70 (Hsc70) and heat-shock protein 72 (Hsp72) are among these homologues, the former
being constitutively expressed and the latter stress-induced.7 Hsc70 slows the clearance of tau,
whereas Hsp72 accelerates degradation.8 Hsp72 has a stronger affinity for tau, yet it is far less
abundant in the brain and is not induced in AD despite the stress experienced by cells.9 When tau
dissociates from microtubules, Hsc70 works to refold tau and reconnect it to microtubules.
Hyperphosphorylated tau is still targeted by Hsc70 although it cannot be properly refolded, and
results in Hsc70 holding on to pathological tau.10
Hsp70s are ATP dependent in substrate bind and release cycles.7, 11 When ATP is bound, Hsp70
engages in rapid on and off rates for substrates, while the ADP bound state experiences slow offrates.7 ATP must hydrolize for the client to stabilize within Hsp70.11 Hsp70 requires the
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assistance of J proteins and nucleotide exchange factors to hydrolize ATP and release ADP,
respectively. Once Hsp70 is in a stable complex with ADP, it is more likely to lead tau to proper
degradation.10-11
3.3 Hsp70 Inhibitors
In order to stabilize the ADP complex of Hsp70, we wanted to seek out known inhibitors of this
chaperone. Hsp70 chaperones are also upregulated in tumors and are required for tumor
survival.12-13 Hsp70 proteins have promiscuous interactions with other proteins.14 Compounds
that modulate Hsp70 protein activity through the ATP binding site or at other sites can help
understand its role in misfolding disorders and cancer.

Figure 3.1 Inhibitors of Hsp70
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The identification of a compound known as PES (phenylethynesulfonamide) was shown to be
toxic to cancer cell lines and it acted through Hsp72 (Figure 3.1) at the substrate binding site. It
altered co-chaperone associations with Hsp72.14 Another small molecule inhibitor, VER-155008,
was found to be active against cancer cells through interactions with Hsp70 near the nucleotide
binding site.14 The compound MKT-077, a rhodacyanine dye derivative, was discovered to bind
near the ATP binding site of mitochondrial Hsp70.12 Its selectivity for the mitochondrial variant
likely stems from its cationic charge. MKT-077 was further found to inhibit proliferation of
cancer cell lines.12 Preclinical tests in rats revealed low toxicity below 3 mg/kg per day, but renal
impairment above that dose. Phase I clinical trials showed renal toxicity in patients and trials
were ended due to a failure to reach a therapeutic dose following administration.15 A structurally
similar compound, YM-01, was identified as having anticancer activity.15 It showed increased
activity over MKT-077 due to its greater cytosolic presence.
Despite the Phase I trial failures of MKT-077, research into its Hsp70 interactions remained
strong. Gestwicki and Dickey later discovered that MKT-077 promotes Hsp70-led tau
degradation in HeLa cells.12 MKT-077 does not cross the BBB, so it could not be used as a
functional CNS drug.16 A new compound, YM-08 (Figure 3.1), was made as a neutral analog
of16 MKT-077 upon the removal of the ethyl from the pyridinium.16 YM-08 was discovered to
cross the BBB while maintaining some anti-tau activity, although it was not as potent as MKT077. This suggested that either the cationic charge or the alkyl groups in that region were partly
responsible for the anti-tau activity.
Gestwicki’s group has led an effort to create new rhodacyanine derivatives based on this
information.17 The benzothiazole component is further deemed necessary for activity. Moreover,
YM-08 suggested that alkyl groups on the cationic nitrogen may be necessary. Most work done
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to date has focused on different groups attached to either a pyridinium or thiazolium ring.
Additionally, changes to the ethyl group in the rhodanine ring have been studied, with no general
trend observed to how it affects potency.17-18 Very little work has been done with the addition of
halogen or small groups to the benzothiazole ring.
3.4 Probing New Regions for Modification
A docking study done on Hsp70 was done by the Gestwicki and Dickey groups. It suggested that
a rhodacyanine derivative known as JG-48 interacts with Hsp70 near the ATP binding site and it
may not necessarily interfere with nucleotide binding (Figure 3.2).7 The results of the docking
study suggested a potential for optimization of these rhodacyanine derivatives. There is a channel
opening near the position where the benzothiazole ring is predicted to sit within Hsp70.7

Figure 3.2 Docking Study of JG-48 on Hsp707
The benzene ring of the benzothiazole is referred to as ring A in this manuscript, and the position
of the chlorine is referred to as position 6 or carbon 6. One of the goals of our research was to
make changes to this position in hopes of improving binding interactions with Hsp70 and
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improving degradation of tau in biological assays. The compound known as JG-98 was chosen as
the lead compound for optimization due to its strong tau clearing effect.
We also wanted to make changes to the thiazolium ring by replacing it with a neutral imidazole.
This is a structure that has not yet been explored. Previous research of these compounds used
pyridine and thiazole derivatives, so we wanted to create a compound that has an aromatic ring
in that position that also allows for alkyl groups to be attached to the nitrogen without the need
for a cationic charge. Research suggests the removal of the charge can aid in making more BBB
permeable compounds.16
3.5 Synthesis of JG-98 Halide Analogs
Because we chose JG-98 as our lead for modification, our first goal in this project was to
synthesize JG-98 in scalable quantities for use in biological assays. We also needed to compare
JG-98 with published characterization data to ensure our synthetic route worked as indicated for
the JG compounds in the literature.17 We started by making our version of JG-98 with
commercially available 2,4-dichloroaniline and reacted it with potassium ethylxanthate to yield
the corresponding benzothiazole 3.01 (Scheme 3.1).19 The next step was to methylate the thiol on
the benzothiazole and make it into a better leaving group leading to compound 3.02.20 3.02 was
then methylated at the nitrogen using methyl tosylate under heated conditions. Upon cooling the
reaction to room temperature, a solution of 3-ethylrhodanine was added, then triethylamine was
added with further cooling. This set of steps added the rhodanine to the benzothiazole to create
the conjugated heterocyclic 3-ring system in compound 3.03.21 Compounds in the same class as
3.03 are bright yellow and extremely insoluble in a wide range of organic solvents. Purification
of this compound was simple, as everything else could be rinsed off from a filtration. However,
obtaining NMR spectra was more difficult since the solvent of choice in the literature, DMSO,
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does not dissolve enough of the compound to observe nuclei even in high field NMR
instruments. Dichloromethane was found to be the best solvent for dissolving this type of
compounds, and thus NMR spectra were run in deuterated dichloromethane for optimal results.

Scheme 3.1 Synthesis of JG-98 as a Bromide Salt
The next step was to set up the rhodanine derivative 3.03 to add the remaining rings. 3.03 was
methylated once more with methyl tosylate to create the thiomethyl derivative 3.04 as a tosylate
salt.21 Separately, 3-benzyl-2-methylthiazol-3-ium bromide was prepared from 2-methylthiazole
and benzyl bromide, which was collected by filtration to form 3.05 as white crystals and as a

46

bromide salt.22 The two salts, 3.04 and 3.05, were combined and heated with additional
triethylamine to make compound 3.06, which was collected by filtration to give an orange
solid.21 1H NMR of this solid indicated that the tosylate was not present, which means this was
collected as a bromide salt. Trace amounts of the starting materials from prior synthetic steps
were also detected, namely 3.03 and to a lesser extent 3.04. For all biological assays and NMR
spectra, final products in the form of 3.06 were further purified by column chromatography.

Scheme 3.2 Synthesis of Aryl Halide Analogs
Compound 3.06 was made as our version of JG-98, with the only difference being the salt form.
Position 6 of ring A in JG-98 and our compound 3.06 (also labeled as AL6 in biological assays)
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was our primary goal for modification. We made a series of the other three aryl halides using the
exact methodology described above. As shown in Scheme 3.2, we made the aryl bromide analog
3.11 (also labeled as AL16 in biological assays), the aryl fluoride analog 3.17 (AL29), and aryl
iodide analog 3.22 (AL60). The purpose behind making aryl halides was to convert them to new
final compounds in a single step using organometallic catalysts and reagents.
3.6 Suzuki coupling
The first attempt at derivatization of position 6 was done with a Suzuki coupling using 3.11 as
the substrate. We wanted to test the size and interactions present at the pocket of Hsp70 to which
these analogs bind. A phenyl ring substituent is roughly the size of a bromine atom in terms of
molecular weight. In contrast to an aryl bromide, a biphenyl ring system was expected to have
different lipophilicity and conformation, so we wanted to explore its effect on Hsp70.23

Scheme 3.3 Suzuki Coupling
The aryl bromide 3.11 was reacted with phenylboronic acid, potassium carbonate, and palladium
tetrakis(triphenylphosphine) using general procedures for a Suzuki coupling.24 This generated
the phenyl analog 3.12 in moderate yield (Scheme 3.3).
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3.7 Permeability Assays

Figure 3.3 PAMPA Plate
In order to test BBB permeability of compounds, we used a BBB protocol for a Parallel Artificial
Membrane Permeability Assay developed by Pion. The protocol uses sandwich plates with a
donor plate and an acceptor plate separated by a semipermeable membrane that mimics the BBB
(Figure 3.3). Compounds were loaded on a donor plate and the acceptor plate was placed on top.
The UV signals from the donor and acceptor plates were measured prior to incubation.
Incubation and constant stirring allowed compounds to transfer through the membrane into the
acceptor plate. After one hour, the UV signals of the donor and acceptor plates were measured
and used to determine how much of the compound transferred to the acceptor plate. The tests
were done in triplicate for the compounds synthesized to that date.
Table 3.1 shows the results from this permeability assay. The aryl halides that were tested were
found to not be permeable though this artificial membrane. Interestingly, compound 3.12 was
found to be >39% permeable, suggesting that lipophilic groups attached to this position of ring A
overcame some of the permeability challenges of these cationic compounds. This showed
promise in developing further analogs at this position to improve upon the BBB permeability of
these compounds.
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Table 3.1 Results of Permeability Assay

Compound

Compound Structure

Average
Permeability

% Permeability

Membrane

-

Not permeable

-

68.42

39.82

Not permeable

-

3.06
(AL6)

3.11
(AL16)

3.12
(AL17)

3.17
(AL29)

3.8 Organometallic Coupling Attempts
Data from the permeability assays showed that the phenyl analog was able to permeate a bloodbrain barrier mimic whereas various aryl halides did not. One of the goals of this research was to
improve blood-brain barrier permeability, so this was a step in the right direction toward further
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analog development. However, preliminary data at the time showed that 3.12 was not as active in
tau reduction as the aryl halides. One hypothesis behind this was that the biphenyl ring system
was oriented in a way that did not interact optimally with Hsp70. A biphenyl ring system is flat
to allow for full conjugation of pi electrons. The X-ray crystal structure of MKT-077 illustrates
the coplanarity of rings A, B, and rhodanine.23 An additional phenyl ring attached to ring A was
therefore implied to be coplanar. In order to combine these two pieces of information, we
decided to make new analogs with a flexible atom that would allow for the rotation of
substituents at that position so they could interact optimally within the pocket of Hsp70.
The next attempt at derivatizing 3.11 was done using Buchwald-Hartwig couplings to establish
amines at position 6. Benzylamine was used with Pd2(dba)3 and Xantphos as a ligand but
compound 3.23 was not successfully synthesized (Scheme 3.4).25 Different palladium sources
and ligands were also used without success. We decided to try this coupling an earlier synthetic
step as a starting point rather than a final compound. The synthesis of 3.24 from 3.08 was
successful using the same conditions described above. The next step encountered a problem in
which a double methylation occurred, indicated by mass spectrometry, to form compound 3.25.
The next methylation was attempted but did not successfully yield compound 3.26. Instead, it is
believed the methylation occurred at the nitrogen. Due to overmethylation of the amine in
various steps, this route was abandoned.
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Scheme 3.4 Organometallic Coupling Attempts
Other attempts at introducing diversity at position 6 included attempts at a Sonogashira coupling.
We hoped that an alkyne at this position could act like an extension through the narrowing of the
pocket of Hsp70. Initial attempts to derivatize on 3.11 proved unsuccessful and we instead used
3.08 as a starting point. Compound 3.08 was reacted with 1-pentyne, palladium
tetrakis(triphenylphosphine), and copper iodide.26 Interistingly, substitution was not observed at
the bromo, and instead the thiomethyl was displaced (3.27). This was indicated by the continued
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presence of a 1:1 ratio of the isotopes of bromine by mass spectrometry. Ultimately, attempts at
establishing an alkyne at this position were abandoned.
3.9 Ether Analogs
The next series of organometallic reactions that we performed were Ullmann-type couplings
using copper iodide and iron (III) acetylacetonate (Fe(acac)3) co-catalysts to make ethers at
position 6 of ring A. 4-bromo-2-chloroaniline was used as the aryl halide substrate and was
reacted with phenol or methanol heated in the presence of base to test reaction conditions
(Scheme 3.5).27 Conventional heating was done initially for both reactions. The coupling of
phenol and the substrate successfully yielded compound 3.28 in modest yields. The coupling
using methanol using conventional heating yielded only trace product after multiple days of
heating. A microwave reactor was used in order to optimize reaction conditions. Additionally,
the addition of sodium methoxide proved useful for increasing yields. The reaction was heated
over multiple 30 to 45-minute cycles in the microwave reactor. 8 cycles of heating were enough
to isolate the product, compound 3.29. Heating beyond 8 cycles increased the amount of dimer
byproducts from the reaction, in which the aniline was coupled with an aryl bromide. A similar
set of conditions for the synthesis of 3.29 was used to make the ethyl ether 3.30. Coupling of
ethanol to the aryl halide was challenging and yields were abysmal even with multiple
modifications. A total of 12 reactions consisting of 6-16 cycles each and totaling 114 microwave
cycles were performed to obtain roughly 0.6 g of the ethyl ether 3.30. The synthesis of the ethyl
ether analog was eventually abandoned.
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Scheme 3.5 Ullmann Coupling
The success in these test reactions prompted attempts to use an Ullmann-type coupling on 3.11 to
obtain late-stage diversity. This did not yield the desired product. Attempts to create diversity
through various ether linkages were made on earlier synthetic steps of the aryl bromide series of
compounds. While coupling on compound 3.09 was successful, purification was difficult owing
partly to the insolubility of both the leftover starting material and the product. Ultimately, we
decided to continue the synthesis of new ether analogs starting from the Ullmann-type coupling
on 4-bromo-2-chloroaniline.
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Scheme 3.6 Synthesis of Ether Analogs
After the synthesis of 3.28 and 3.29, each compound was carried through the same procedures to
build up the remaining rings as described for the aryl halide analogs, illustrated by Scheme 3.6.
The synthetic steps provided similar results in percent yield and reaction characteristics such as
color and solubility. The result was the synthesis of final compounds 3.35 as the phenyl ether
analog (labeled as AL61 in biological assays) and 3.40 as the methoxy analog (AL69). Following
the success of these two syntheses, we went back to the Ullmann-type couplings to make new
ethers to carry forward. 2,2,2-Trifluoroethanol was reacted in the same set of conditions
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described previously to yield trifluoroethyl (TFE) ether 3.41. Similarly, benzyl alcohol was
reacted in the same conditions to make the benzyl ether 3.47. Each of these ethers was carried
forward in conditions described above to yield final compound 3.46 as the TFE ether (AL70) and
3.52 as the benzyl ether (AL80).
3.10 Imidazole Analogs
The other area where we wished to make changes to JG-98 was in the thiazolium ring. All final
compounds made so far contained a cationic nitrogen and compounds were quaternary
ammonium bromide salts. The electrons in the pi bond of the cationic nitrogen are in conjugation
with the exocyclic vinyl bond attached to the rhodanine ring and has the potential to resonate
with the rhodanine nitrogen. We were interested in removing the positive charge on these
compounds and creating an analog with a neutral imidazole moiety. The synthesis of all the
thiazole analogs adds a benzylated thiazolium to the rhodanine-tosylate salts. A 2methylimidazole is not deprotonated as easily as a 2-methylthiazolium due to its neutral charge.
We wanted to create a better nucleophile out of the imidazole, so we chose to add it to the
rhodanine-tosylate salts via a Grignard reaction. Our synthetic plan involved making the Nbenzylimidazole Grignard reagent in Scheme 3.7.

Scheme 3.7 Grignard Addition of Imidazole Moiety
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The original synthetic plan was to start with 1-benzyl-2-methyl-1H-imidazole and brominate the
methyl with NBS. This reaction did not go as planned and bromination occurred repeatedly at the
benzylic carbon instead. We changed the synthetic route to start with imidazole, and benzylating
to create compound 3.55.28 Next, we added a formyl group on the imidazole by deprotonating
with n-butyllithium and adding DMF to generate 3.56.29 The aldehyde was reduced to alcohol
3.57,29 and then made into the alkyl bromide 3.58 to prepare the Grignard reagent.30 As shown in
Scheme 3.8, the remaining steps are to add the brominated imidazole to magnesium turnings to
make the Grignard reagent, then add it to the tosylate salt 3.04.31

Scheme 3.8 Synthesis of Imidazole Analog
3.11 Results and Discussion
Biological testing of compounds was done by the former Dickey lab and currently by the Blair
lab at the Byrd Alzheimer’s Institute. Initial comparisons of our synthesized version of JG-98,
compound 3.06, behaved like JG-98 in assays measuring the clearance of tau. The western blot
in Figure 3.4 shows the clearance of tau at the same concentrations for these two compounds.
This confirmed that the salt form of our rhodacyanine derivatives would not affect the activity.
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Figure 3.4 Comparison of JG-98 and AL6
Western blot comparing the reduction of tau by treatment with JG-98 Chloride
(JG-98) or JG-98 Bromide (AL6). The gel indicates a reduction of pTau with
increasing concentrations of the rhodacyanine.
Most of the biological testing has been done on the novel ether compounds and the aryl iodide in
comparison with JG-98. The compounds tested are: aryl iodide 3.22 (AL60), phenyl ether 3.35
(AL61), methyl ether 3.40 (AL69), and TFE ether 3.46 (AL70). Compounds have been tested on
primary cortical neurons, iHek cells expressing P301L tau, and ex vivo mouse brain slices.
Cytotoxicity has been tested on SH-SY5Y human bone marrow neuroblastoma cells.
A cell culture experiment was done by using tetracycline-regulatable P301L 4R0N tau stably
expressing HEK293T cells with these compounds. The iHEKP301L cells were induced for 48
hours total to express tau. The cells were then treated with the rhodacyanine derivatives at the
indicated doses for 24 h. The Western blots on Figure 3.5 show the clearance of tau and
phosphorylated tau of these four compounds when compared to JG-98. As shown, AL70 (3.26)
clears tau far more effectively than any other compound in the first Western blot, and more so
than our standard, JG-98. AL61 and AL69 also clear total tau and phosphorylated tau at higher
concentrations in the first blot. Additional experiments were performed to obtain data in
triplicate, shown in Figure 3.6. The Western blots shown on Figure 3.6 indicate general trends
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toward reduction of total tau and phosphorylated tau. The data show an effective reduction of
total tau by AL60 and AL69. The last Western blot in Figure 3.6 indicates the moderate
reduction of tau in the cell lysates for AL69 and AL70. A composite graph of the Western blots
was done to measure the relative pT231 tau and total tau reduction (Graph 3.1).
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Figure 3.5 Comparison of AL60, AL61, AL69, and AL70 – Part 1
Tetracycline-regulatable P301L 4R0N tau stably expressing HEK293T cells were
induced with tetracycline hydrochloride and then treated at the indicated doses of
rhodacyanine derivatives. Cells were lysed and run on SDS-PAGE gels.
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Figure 3.6 Comparison of AL60, AL61, AL69, and AL70 – Part 2
Additional Western blots of rhodacyanine derivatives following previously
described methods (Figure 3.5).

Graph 3.1 Densitometry of Western Blots in Figures 3.5 and 3.6
Reduction of pTau and total tau upon treatment of iHEKP301L cells induced to
express tau with rhodacyanine derivatives.
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Graph 3.2 Cytotoxicity Data of AL60, AL61, AL69, and AL70
The graph indicates the toxicity of select rhodacyanine derivatives on SH-SY5Y
human neuronal cells treated for 24 hours at the indicated doses.
Cytotoxicity assays were done on SH-SY5Y human neuronal cells treated for 24 hours with the
same rhodacyanine derivatives used in previous tau reduction assays. A graphical representation
of the percent toxicity is shown on Graph 3.2. There is a slight trend to an increase in toxicity for
AL60, but it is within the error bars. Overall, the data indicate that these compounds are not toxic
to human cells.
Compounds that were considered more active at clearing tau in cell assays were further tested on
ex vivo mouse brain slices. The purpose of these assays is to test how the compounds interact
within brain tissue as opposed to cells. rTg4510 Transgenic mice overexpressing human 4R0N
tau were used for these assays. The Western blot on Figure 3.7 shows the clearance of total tau
and phosphorylated tau of AL61, AL69, and AL70 when compared to JG-98. At higher
concentrations, all three of these compounds clear total tau more effectively than JG-98. The
amount of phosphorylated tau cleared does not show a clear pattern for higher concentrations of
these compounds. AL69 reduces total tau effectively, more so than JG-98. Overall, the trend is
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that these compounds are active at reducing phosphorylated and total tau, and further tests are
underway to validate data.
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Figure 3.7 Ex Vivo Mouse Brain Slice Assays
Brain slices of rTg4510 transgenic mice overexpressing human 4R0N tau were
treated with select rhodacyanine derivatives at the indicated doses. After
treatment, the brain slices were homogenized and prepared for a Western blot.
Two additional tests were done on AL60, AL61, AL69, and AL70. The first of these was a
malachite green assay to measure ATPase activity and to test for the inhibitory effect of these
compounds on the ATP activity of Hsp70 proteins. The methods used were based on previously
published procedures.32 Graph 3.3 shows that at increasing concentration of each of the select
rhodacyanine derivatives, there is an inhibitory effect on the ATPase activity of Hsp70. Of the
compounds tested, AL60 had a slightly stronger inhibitory effect. The docking study mentioned
earlier suggests that rhodacyanine derivatives likely bind near the ATP binding site of Hsp70.
The importance of these assays was to test whether the tau reducing properties of these
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rhodacyanine derivatives is related specifically to Hsp70, whether through modulating ATP
activity or through another mechanism.
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Graph 3.3 ATPase Activity of AL60, AL61, AL69, and AL70
The graph shows the inhibitory effect of select rhodacyanine derivatives on Hsc70
ATPase activity at the indicated doses of each compound.
The second additional assay that was performed on these compounds was a Thioflavin T
aggregation kinetics assay to test for the ability of these compounds to prevent aggregation of
tau. In this assay, the fluorescence dye Thioflavin T is used to detect protein aggregates by
increasing biofluorescence emission.33-34 The aggregation kinetics assay was performed on the
same rhodacyanine derivatives as the ATPase assay. Compounds AL60, AL61, and AL69 have
low fluorescence values as shown in Graph 3.4, meaning they have anti-aggregation effects. The
data suggest that some of these compounds may have anti-aggregation activity independent of
Hsp70 activity.
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Graph 3.4 Thioflavin T Aggregation Kinetics Assay
The graph shows the ability of select rhodacyanine derivatives to prevent tau
aggregation. AL60, AL61, and AL69 exhibit anti-aggregation effects at low
concentrations.
3.12 Conclusions and Future Directions
We have successfully synthesized nine rhodacyanine derivatives related to JG-98. The
development of these compounds was guided by a desire to create compounds more potent at
clearing total tau. Compound 3.46 (AL70) was found to be more potent than JG-98 in multiple
biological assays. Furthermore, one of our initial goals was to improve blood-brain barrier
permeability. We achieved this by installing hydrophobic groups on ring A of rhodacyanine
derivatives. Initial permeability data suggested that 3.12 (AL17) was far more permeable than
aryl halides, although it fell short on its tau-reducing properties. Full permeability data on all
compounds synthesized is an ongoing objective with the latest compounds synthesized as well as
any future analogs developed.
The development of the imidazole analogs can lead to new boundaries in this research. The
cationic analogs are potent in removing tau but also exist with a host of solubility issues. The
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removal of a full cationic charge on drug candidates in general can impact molecular stability,
permeability, and solubility. It is our hope to develop and test novel imidazole analogs with
optimal properties in terms of BBB permeability while maintaining tau-reducing properties.
3.13 Experimental Procedures

Potassium O-ethyl carbonodithioate (4.37 g, 27.3 mmol) and 2,4-dichloroaniline (2.03 g, 12.5
mmol) were added to a 100 mL round bottomed flask containing a stir bar and dissolved in 35
mL of DMF to give a brown solution. The mixture was heated with stirring at 120 °C for 16 h,
and then cooled to room temperature. The reaction mixture was diluted with 100 mL of ice water
and acidified with 35 mL of 1 M HCl. The resulting precipitate was filtered and rinsed three
times with warm 1:1 chloroform:hexane. The second solid was collected and dried to yield 3.01
(2.14 g, 85%) as a tan solid. 1H NMR (500 MHz, DMSO) δ 13.85 (br s, 1H), 7.85 (d, 1H, J=2.0
Hz), 7.43 (dd, 1H, J=2.2, 8.6 Hz), 7.26 (d, 1H, J=8.8 Hz) ppm. 13C NMR (151 MHz, DMSO) δ
190.6, 140.7, 131.5, 129.0, 127.7, 121.9, 113.9 ppm. HRMS m/z: [M+H]+ calcd for C7H5ClNS2
201.9546; found 201.9554.

Compound 3.01 (4.04 g, 20.1 mmol) was added to a 250 mL round bottomed flask containing a
stir bar and was suspended in 155 mL of ethanol. Triethylamine (2.80 mL, 20.1 mmol) and
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methyl iodide (1.26 mL, 20.2 mmol) were added to the suspension. The mixture was heated with
stirring at 85 °C for 1 h, and then cooled to room temperature. The solvent was removed on a
rotary evaporator. The residue was extracted with dichloromethane and washed with 50%
saturated ammonium chloride (2x) and brine (1x). The combined organic layers were dried with
sodium sulfate and concentrated on a rotary evaporator to yield 3.02 (3.49 g, 81%) as tan
crystals. 1H NMR (600 MHz, CDCl3) δ 7.7-7.8 (m, 2H), 7.4-7.5 (m, 1H), 2.81 (br s, 3H) ppm.
C NMR (151 MHz, CDCl3) δ 168.7, 152.0, 136.4, 130.0, 126.8, 122.0, 120.6, 15.9 ppm.

13

HRMS m/z: [M+H]+ calcd for C8H7ClNS2 215.9703; found 215.9716.

Compound 3.02 (1.00 g, 4.64 mmol) and methyl p-toluenesulfonate (1.050 mL, 6.95 mmol) were
added to a 50 mL round bottomed flask containing a stir bar and dissolved in 1.2 mL of anisole.
The mixture was heated with stirring at 120 °C for 4 h, and then cooled to room temperature. 3ethyl-2-thioxothiazolidin-4-one (0.755 g, 4.68 mmol) was dissolved in 17 mL of acetonitrile and
added to the first solution. The reaction was cooled to 0 °C, and triethylamine (1.066 mL, 7.65
mmol) was added dropwise. The mixture was stirred at room temperature for 1 h. The precipitate
was filtered and rinsed with acetonitrile to yield 3.03 (1.10 g, 69%) as a yellow solid. 1H NMR
(600 MHz, DMSO) δ 8.09 (s, 1H), 7.67 (br d, 1H, J=8.7 Hz), 7.56 (br d, 1H, J=8.4 Hz), 4.10 (br
d, 2H, J=7.3 Hz), 3.95 (s, 3H), 1.19 (br t, 2H, J=6.9 Hz) ppm. HRMS m/z: [M+H]+ calcd for
C13H12ClN2OS3 342.9795; found 342.9801.
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Compound 3.03 (1.03 g, 2.99 mmol) and methyl p-toluenesulfonate (1.33 mL, 8.78 mmol) were
added to a 25 mL round bottomed flask containing a stir bar and dissolved in 2 mL of DMF. The
mixture was heated with stirring at 130 °C for 3 h. The reaction was cooled to 95 °C, and 17 mL
of acetone was added. The mixture was further cooled to room temperature with constant
stirring. The precipitate was filtered and rinsed with cold acetone to yield 3.04 (1.42 g, 89%) as a
yellow solid. 1H NMR (600 MHz, DMSO) δ 8.34 (s, 1H), 8.02 (br d, 1H, J=9.1 Hz), 7.7-7.8 (m,
1H), 7.47 (br d, 2H, J=7.6 Hz), 7.11 (br d, 2H, J=7.6 Hz), 4.22 (s, 3H), 4.1-4.2 (m, 2H), 3.07 (s,
3H), 2.29 (s, 3H), 1.33 (br t, 3H, J=6.9 Hz) ppm. 13C NMR (151 MHz, DMSO) δ 178.6, 163.3,
161.6, 146.4, 139.9, 138.0, 130.2, 128.7, 128.5, 128.4, 126.0, 123.4, 115.8, 86.4, 43.0, 36.6, 21.3,
16.7, 12.2 ppm. HRMS m/z: [M]+ calcd for C14H14ClN2OS3 356.9957; found 356.9955.

2-Methylthiazole (0.999 g, 10.1 mmol) and benzyl bromide (1.20 mL, 10.1 mmol) were added to
a 25 mL round bottomed flask containing a stir bar and dissolved in 6 mL of acetonitrile. The
mixture was heated with stirring at 75 °C for 4 h, and then cooled to room temperature. The
solvent was removed on a rotary evaporator. The crude precipitate was collected by vacuum
filtration and washed with cold diethyl ether to yield 3.05 (1.46 g, 54%) as a white solid. 1H
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NMR (500 MHz, DMSO) δ 8.40 (d, 1H, J=3.9 Hz), 8.13 (d, 1H, J=3.9 Hz), 7.3-7.5 (m, 5H), 5.68
(s, 2H), 2.97 (s, 3H) ppm.

13

C NMR (126 MHz, DMSO) δ 172.5, 137.7, 133.7, 129.6, 129.4,

128.6, 123.8, 55.1, 16.0 ppm. HRMS m/z: [M]+ calcd for C11H12NS 190.0690; found 190.0698.

Compound 3.04 (1.20 g, 2.27 mmol) and 3.05 (0.621 g, 2.30 mmol) were added to a 25 mL
round bottomed flask containing a stir bar and suspended in 11 mL of acetonitrile. The mixture
was heated to 70 °C, and then triethylamine (2.08 mL, 14.9 mmol) was added dropwise. The
reaction was stirred at 70 °C for 16 h, and then cooled to room temperature. Ethyl acetate was
added to the mixture. The precipitate was collected by vacuum filtration and washed with cold
ethyl acetate to yield 3.06 (0.950 g, 72%) as an orange solid. Samples for spectra and biological
assays were further purified by flash column chromatography (DCM, then 1-5% methanol in
DCM). 1H NMR (600 MHz, DMSO) δ 8.27 (d, 1H, J=4.0 Hz), 8.08 (d, 1H, J=1.8 Hz), 7.92 (d,
1H, J=4.0 Hz), 7.69 (d, 1H, J=8.7 Hz), 7.56 (dd, 1H, J=2.0, 8.5 Hz), 7.4-7.5 (m, 2H), 7.3-7.4 (m,
3H), 6.53 (s, 1H), 5.77 (s, 2H), 4.0-4.1 (m, 5H), 0.98 (br t, 3H, J=7.1 Hz) ppm. 13C NMR (151
MHz, DMSO) δ 164.1, 161.8, 157.1, 153.8, 140.0, 135.8, 135.1, 129.6, 128.9, 128.6, 128.3,
127.9, 127.8, 122.6, 115.4, 114.0, 84.0, 81.4, 53.6, 39.0, 35.3, 12.3 ppm. HRMS m/z: [M]+ calcd
for C24H21ClN3OS3 498.0535; found 498.0552.
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Potassium O-ethyl carbonodithioate (8.58 g, 53.5 mmol) and 4-bromo-2-chloroaniline (4.99 g,
24.2 mmol) were added to a 250 mL round bottomed flask containing a stir bar and dissolved in
75 mL of DMF to give a brown solution. The mixture was heated with stirring at 120 °C for 16
h, and then cooled to room temperature. The reaction mixture was diluted with 225 mL of ice
water and acidified with 75 mL of 1 M HCl. The resulting precipitate was filtered and rinsed
three times with warm 1:1 chloroform:hexane. The second solid was collected and dried to yield
3.07 (5.42 g, 91%) as a tan solid. 1H NMR (500 MHz, DMSO) δ 13.84 (br s, 1H), 7.97 (d, 1H,
J=2.0 Hz), 7.54 (dd, 1H, J=2.0, 8.8 Hz), 7.20 (d, 1H, J=8.3 Hz) ppm.

13

C NMR (126 MHz,

DMSO) δ 190.5, 141.0, 131.9, 130.4, 124.6, 116.8, 114.3 ppm. HRMS m/z: [M+H]+ calcd for
C7H5BrNS2 245.9041; found 245.9047.

Using conditions identical to those described above for compound 3.02, 3.07 (2.03 g, 8.24 mmol)
was converted to 3.08 to yield tan crystals (1.88 g, 88%). 1H NMR (600 MHz, CDCl3) δ 7.91 (s,
1H), 7.73 (d, 1H, J=8.7 Hz), 7.5-7.6 (m, 1H), 2.81 (s, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ
168.8, 152.3, 136.8, 129.5, 123.5, 122.4, 117.5, 15.9 ppm. HRMS m/z: [M+H]+ calcd for
C8H7BrNS2 259.9198; found 259.9204.
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Using conditions identical to those described above for compound 3.03, 3.08 (2.54 g, 9.76 mmol)
was converted to 3.09 to yield a yellow solid (3.04 g, 80%). 1H NMR (500 MHz, CD2Cl2) δ 7.77
(d, 1H, J=2.0 Hz), 7.56 (dd, 1H, J=2.0, 8.8 Hz), 7.11 (d, 1H, J=8.8 Hz), 4.20 (q, 2H, J=7.3 Hz),
3.87 (s, 3H), 1.29 (t, 3H, J=7.1 Hz) ppm. HRMS m/z: [M+H]+ calcd for C13H12BrN2OS3
386.9289; found 386.9298.

Using conditions identical to those described above for compound 3.04, 3.09 (0.974 g, 2.51
mmol) was converted to 3.10 to yield a yellow solid (1.26 g, 87%). 1H NMR (600 MHz, DMSO)
δ 8.46 (d, 1H, J=2.2 Hz), 7.95 (d, 1H, J=9.1 Hz), 7.86 (dd, 1H, J=2.0, 8.9 Hz), 7.47 (d, 2H, J=8.0
Hz), 7.10 (d, 2H, J=7.6 Hz), 4.21 (s, 3H), 4.17 (br d, 2H, J=7.6 Hz), 3.06 (s, 3H), 2.29 (s, 3H),
1.33 (t, 3H, J=7.3 Hz) ppm.
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C NMR (151 MHz, DMSO) δ 178.7, 163.3, 161.4, 146.4, 140.2,

138.0, 131.4, 128.8, 128.5, 126.2, 126.0, 118.1, 116.1, 86.4, 43.0, 36.6, 21.3, 16.7, 12.2 ppm.
HRMS m/z: [M]+ calcd for C14H14BrN2OS3 400.9452; found 400.9458.
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Using conditions identical to those described above for compound 3.06, 3.10 (1.01 g, 1.76 mmol)
was converted to 3.11 to yield an orange solid (0.787 g, 72%). 1H NMR (600 MHz, DMSO) δ
8.27 (d, 1H, J=4.0 Hz), 8.20 (s, 1H), 7.92 (br d, 1H, J=3.6 Hz), 7.68 (br d, 1H, J=8.7 Hz), 7.63
(d, 1H, J=9.1 Hz), 7.4-7.5 (m, 2H), 7.3-7.4 (m, 3H), 6.53 (s, 1H), 5.77 (s, 2H), 4.0-4.1 (m, 5H),
0.98 (br t, 3H, J=7.1 Hz) ppm. 13C NMR (151 MHz, DMSO) δ 164.1, 161.8, 157.0, 153.8, 140.4,
135.8, 135.1, 130.5, 129.6, 128.9, 128.7, 127.9, 125.3, 116.3, 115.4, 114.4, 84.1, 81.5, 53.6, 39.0,
35.3, 12.3 ppm. HRMS m/z: [M]+ calcd for C24H21BrN3OS3 542.0030; found 542.0046.

Compound 3.11 (98.2 mg, 0.158 mmol) and 1 mL of toluene were added to a 10 mL round
bottomed flask containing a stir bar. Sodium carbonate (41.1 mg, 0.388 mmol) was dissolved in
0.2 mL of water and was added to the reaction. Phenyl boronic acid (30.6 mg, 0.251 mmol) was
dissolved in 0.8 mL of ethanol and was added to the reaction flask. The mixture was
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deoxygenated under reduced pressure and the flask was backflushed with argon for several
cycles. Pd(PPh3)4 (16.9 mg, 0.015 mmol) was added to the reaction mixture and the reaction was
flushed with argon. The mixture was heated with stirring to 110 °C for 8 h, then allowed to cool
to room temperature. The mixture was diluted with water and extracted with DCM. The organic
phase was dried with magnesium sulfate and concentrated on a rotary evaporator. The residue
was purified by flash column chromatography (DCM, then 1-10% methanol in DCM) to yield
3.12 (29.9 g, 31%) as a red-orange solid. 1H NMR (500 MHz, DMSO) δ 8.2-8.3 (m, 2H), 7.8-7.9
(m, 2H), 7.7-7.8 (m, 3H), 7.3-7.5 (m, 8H), 6.52 (s, 1H), 5.74 (s, 2H), 4.15 (s, 3H), 4.08 (br d, 2H,
J=7.1 Hz), 0.97 (br t, 3H, J=7.1 Hz) ppm.

13

C NMR (151 MHz, DMSO) δ 164.0, 161.7, 157.2,

153.8, 140.3, 139.3, 136.7, 135.7, 135.1, 129.6, 129.5, 128.9, 127.9, 127.8, 127.1, 127.0, 126.4,
120.7, 115.2, 113.1, 83.9, 81.3, 57.7, 53.5, 35.3, 12.3 ppm. HRMS m/z: [M]+ calcd for
C30H26N3OS3 540.1238; found 540.1259.

Potassium O-ethyl carbonodithioate (7.28 g, 45.4 mmol) and 2-chloro-4-fluoroaniline (2.46 mL
[density = 1.219 g/mL], 20.6 mmol) were added to a 250 mL round bottomed flask containing a
stir bar and dissolved in 62 mL of DMF to give a brown solution. The mixture was heated with
stirring at 120 °C for 16 h, and then cooled to room temperature. The reaction mixture was
diluted with 200 mL of ice water and acidified with 65 mL of 1 M HCl. The resulting precipitate
was filtered and rinsed three times with warm 1:1 chloroform:hexane. The second solid was
collected and dried to yield 3.13 (3.11 g, 81%) as a tan solid. 1H NMR (600 MHz, DMSO) δ
13.81 (br s, 1H), 7.67 (br d, 1H, J=8.0 Hz), 7.2-7.4 (m, 2H) ppm. 13C NMR (151 MHz, DMSO,
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fluorine splitting δ 190.4, 160.4, 158.8, 138.5, 131.3, 131.2, 115.3, 115.1, 113.9, 113.8, 109.5,
109.3 ppm. HRMS m/z: [M+H]+ calcd for C7H5FNS2 185.9842; found 185.9850.

Using conditions identical to those described above for compound 3.02, 3.13 (2.01 g, 10.8 mmol)
was converted to 3.14 to yield tan crystals (2.04 g, 94%). 1H NMR (600 MHz, CDCl3) δ 7.71
(dd, 1H, J=4.7, 9.1 Hz), 7.3-7.4 (m, 1H), 7.05 (dt, 1H, J=2.5, 8.9 Hz), 2.70 (s, 3H) ppm.

13

C

NMR (151 MHz, CDCl3, fluorine splitting) δ 167.5, 167.5, 160.6, 159.0, 150.0, 136.1, 136.1,
122.1, 122.1, 114.4, 114.3, 107.6, 107.4, 16.0 ppm. HRMS m/z: [M+H]+ calcd for C8H7FNS2
199.9998; found 200.0013.

Using conditions identical to those described above for compound 3.03, 3.14 (2.03 g, 10.2 mmol)
was converted to 3.15 to yield a yellow solid (2.85 g, 85%). 1H NMR (600 MHz, DMSO) δ 7.98.0 (m, 1H), 7.68 (br dd, 1H, J=4.2, 8.9 Hz), 7.4-7.5 (m, 1H), 4.10 (q, 2H, J=7.1 Hz), 3.96 (s,
3H), 1.19 (br t, 3H, J=7.1 Hz) ppm. 13C NMR (151 MHz, DMSO) δ 187.4, 165.1, 155.3, 137.6,
115.2, 115.0, 113.9, 113.9, 110.2, 110.0, 83.7, 35.3, 12.5 ppm. HRMS m/z: [M+H]+ calcd for
C13H12FN2OS3 327.0090; found 327.010.
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Using conditions identical to those described above for compound 3.04, 3.15 (0.758 g, 2.32
mmol) was converted to 3.16 to yield a yellow solid (1.10 g, 93%). 1H NMR (600 MHz, DMSO)
δ 8.13 (dd, 1H, J=2.4, 8.2 Hz), 8.05 (dd, 1H, J=4.2, 9.3 Hz), 7.59 (dt, 1H, J=2.5, 8.9 Hz), 7.47
(d, 2H, J=8.0 Hz), 7.10 (d, 2H, J=7.6 Hz), 4.23 (s, 3H), 4.17 (q, 2H, J=7.3 Hz), 3.06 (s, 3H), 2.28
(s, 3H), 1.33 (t, 3H, J=7.3 Hz) ppm.

C NMR (151 MHz, DMSO, fluorine splitting) δ 178.2,

13

163.2, 161.6, 160.7, 159.1, 146.4, 138.0, 137.6, 128.5, 126.0, 116.6, 116.4, 116.0, 115.9, 110.7,
110.5, 86.2, 42.9, 36.7, 21.2, 16.6, 12.3 ppm. HRMS m/z: [M]+ calcd for C14H14FN2OS3
341.0252; found 341.0256.

Using conditions identical to those described above for compound 3.06, 3.16 (0.399 g, 0.778
mmol) was converted to 3.17 to yield an orange solid (0.345 g, 79%). 1H NMR (500 MHz,
DMSO) 8.23 (dd, 1H, J=1.5, 3.9 Hz), 7.8-8.0 (m, 2H), 7.70 (br dd, 1H, J=2.9, 8.8 Hz), 7.3-7.5
(m, 6H), 6.51 (s, 1H), 5.74 (s, 2H), 4.0-4.1 (m, 5H), 0.95 (br t, 3H, J=6.8 Hz) ppm.

13

C NMR

(151 MHz, DMSO) δ 164.1, 161.7, 157.5, 153.9, 137.6, 135.7, 135.1, 129.6, 129.6, 128.9, 127.9,
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115.2, 114.0, 114.0, 110.1, 109.9, 83.9, 81.1, 53.5, 39.0, 35.5, 12.3 ppm. HRMS m/z: [M]+ calcd
for C24H21FN3OS3 482.0831; found 482.0853.

Potassium O-ethyl carbonodithioate (2.80 g, 17.4 mmol) and 2-chloro-4-iodoaniline (1.99 g, 7.85
mmol) were added to a 100 mL round bottomed flask containing a stir bar and dissolved in 23
mL of DMF to give a brown solution. The mixture was heated with stirring at 120 °C for 16 h,
and then cooled to room temperature. The reaction mixture was diluted with 75 mL of ice water
and acidified with 25 mL of 1 M HCl. The resulting precipitate was filtered and rinsed three
times with warm 1:1 chloroform:hexane. The second solid was collected and dried to yield 3.18
(1.81 g, 78%) as a tan solid. 1H NMR (600 MHz, DMSO) 13.83 (br s, 1H), 8.11 (s, 1H), 7.71 (br
d, 1H, J=8.4 Hz), 7.10 (d, 1H, J=8.4 Hz) ppm.

13

C NMR (151 MHz, DMSO) δ 190.3, 141.4,

136.1, 132.1, 130.2, 114.6, 88.6 ppm. HRMS m/z: [M]+ calcd for C7H4INS2 292.8830; found
292.8834.

Using conditions identical to those described above for compound 3.02, 3.18 (1.15 g, 3.92 mmol)
was converted to 3.19 to yield tan crystals (1.12 g, 93%). 1H NMR (600 MHz, CDCl3) δ 8.00 (s,
1H), 7.62 (d, 1H, J=8.3 Hz), 7.52 (d, 1H, J=8.4 Hz), 2.72 (s, 3H) ppm.

13

C NMR (151 MHz,

CDCl3) δ 168.9, 152.8, 137.3, 135.2, 129.4, 122.8, 87.9, 15.9 ppm. HRMS m/z: [M+H]+ calcd
for C8H7INS2 307.9059; found 307.9080.
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Using conditions identical to those described above for compound 3.03, 3.19 (0.747 g, 2.43
mmol) was converted to 3.20 to yield a yellow solid (0.946 g, 90%). 1H NMR (600 MHz,
CD2Cl2) δ 7.84 (s, 1H), 7.6-7.7 (m, 1H), 6.91 (d, 1H, J=8.7 Hz), 4.11 (d, 2H, J=6.9 Hz), 3.77 (s,
3H), 1.21 (br s, 3H) ppm. HRMS m/z: [M+H]+ calcd for C13H12IN2OS3 434.9151; found
434.9158.

Using conditions identical to those described above for compound 3.04, 3.20 (0.902 g, 2.07
mmol) was converted to 3.21 to yield a yellow solid (1.09 g, 85%). 1H NMR (600 MHz, DMSO)
δ 8.58 (d, 1H, J=1.5 Hz), 7.98 (dd, 1H, J=1.5, 8.7 Hz), 7.80 (d, 1H, J=9.1 Hz), 7.47 (d, 2H, J=8.0
Hz), 7.10 (d, 2H, J=8.0 Hz), 4.1-4.2 (m, 5H), 3.06 (s, 3H), 2.28 (s, 3H), 1.32 (t, 3H, J=7.3 Hz)
ppm.

13

C NMR (151 MHz, DMSO) δ 178.5, 163.2, 161.1, 146.4, 140.6, 138.0, 137.0, 131.8,

128.9, 128.5, 125.9, 116.2, 90.2, 86.3, 43.0, 36.4, 21.3, 16.7, 12.2 ppm. HRMS m/z: [M]+ calcd
for C14H14IN2OS3 448.9313; found 448.9307.
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Using conditions identical to those described above for compound 3.06, 3.21 (0.904 g, 1.46
mmol) was converted to 3.22 to yield an orange solid (0.841 g, 87%). 1H NMR (600 MHz,
DMSO) δ 8.29 (d, 1H, J=1.7 Hz), 8.24 (d, 1H, J=4.1 Hz), 7.89 (br d, 1H, J=3.9 Hz), 7.79 (br dd,
1H, J=1.7, 8.7 Hz), 7.4-7.5 (m, 3H), 7.3-7.4 (m, 2H), 7.09 (br d, 1H, J=7.8 Hz), 6.50 (s, 1H),
5.74 (s, 2H), 4.0-4.2 (m, 5H), 0.95 (br t, 3H, J=7.1 Hz) ppm.

13

C NMR (151 MHz, DMSO) δ

164.0, 161.7, 156.7, 153.7, 140.7, 136.1, 135.7, 135.0, 130.8, 129.6, 128.9, 128.5, 127.9, 125.9,
115.3, 114.6, 88.0, 84.0, 81.4, 53.5, 35.1, 12.2 ppm. HRMS m/z: [M]+ calcd for C24H21IN3OS3
589.9891; found 589.9912.

4-Bromo-2-chloroaniline (2.03 g, 9.83 mmol), phenol (1.38 g, 14.7 mmol), potassium carbonate
(4.06 g, 29.4 mmol), CuI (0.0512 g, 0.269 mmol), Fe(acac)3 (0.516 mL, 0.750 M in DMF, 0.388
mmol) and 10 mL of DMF were added to a 50 mL screw cap reaction vial containing a stir bar.
The mixture was flushed with argon, sealed, and heated with stirring to 135 °C for 1 day, then
allowed to cool to room temperature. The mixture was diluted with diethyl ether and filtered over
a pad of celite. The filtrate was washed with brine (3x). The combined organic layers were dried
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with sodium sulfate and concentrated on a rotary evaporator. The residue was purified by flash
column chromatography (3:7 DCM:hexanes) to yield 3.28 (0.975 g, 45%) as a brown oil. 1H
NMR (400 MHz, CDCl3) δ 7.3 (m, 2H), 7.0-7.1 (m, 1H), 6.99 (d, 1H, J=2.6 Hz), 6.93 (d, 2H,
J=7.9 Hz), 6.8 (m, 1H), 6.73 (s, 1H), 3.91 (br s, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 158.2,
148.5, 139.3, 129.6, 122.6, 121.0, 119.6, 117.5, 116.4 ppm. HRMS m/z: [M+H]+ calcd for
C12H11ClNO 220.0524; found 220.0540.

4-Bromo-2-chloroaniline (1.01 g, 4.91 mmol), sodium methoxide (0.584 g, 10.8 mmol),
potassium carbonate (2.01 g, 14.5 mmol), CuI (0.0241 g, 0.127 mmol), Fe(acac)3 (0.258 mL,
0.750 M in DMF, 0.194 mmol), 3 mL of methanol, and 2.5 mL of DMF were added to a 30 mL
microwave vial containing a stir bar. The mixture was flushed with argon and heated in the
microwave reactor at 150 °C for 40 minutes, then allowed to cool to 55 °C. Seven more cycles of
microwave heating and cooling were performed, and then the reaction was cooled to room
temperature. The mixture was diluted with diethyl ether and filtered over a pad of celite. The
filtrate was washed with brine (3x). The combined organic layers were dried with sodium sulfate
and concentrated on a rotary evaporator. The residue was purified by flash column
chromatography (30% DCM in hexanes) to yield 3.29 (0.232 g, 30%) as a brown oil. HRMS
m/z: [M+H]+ calcd for C7H9ClNO 158.0367; found 158.0376.
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Sodium hydride (60% in mineral oil, 0.322 g, 8.05 mmol) was added slowly to 3 mL of ethanol
in a 30 mL microwave vial containing a stir bar and cooled in an ice-water bath. The mixture
was stirred for 10 minutes, and then warmed to room temperature. 2-chloro-4-iodoaniline (1.01
g, 3.97 mmol), potassium carbonate (1.64 g, 11.9 mmol), CuI (15.7 mg, 0.082 mmol), Fe(acac)3
(0.210 mL, 0.750 M in DMF, 0.158 mmol), and 2 mL of DMF were added to the microwave
vial. The mixture was flushed with argon and heated in the microwave reactor at 165 °C for 40
minutes, then allowed to cool to 55 °C. Seven more cycles of microwave heating and cooling
were performed, and then the reaction was cooled to room temperature. The mixture was diluted
with diethyl ether and filtered over a pad of celite. The filtrate was washed with brine (3x). The
combined organic layers were dried with sodium sulfate and concentrated on a rotary evaporator.
The residue was purified by flash column chromatography (1:1 DCM:hexanes) to yield 3.30
(0.095 g, 14%) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 6.82 (d, 1H, J=2.3 Hz), 6.6-6.7 (m,
2H), 3.92 (q, 2H, J=6.9 Hz), 1.35 (br t, 3H, J=7.0 Hz) ppm.

13

C NMR (151 MHz, CDCl3) δ

152.0, 136.6, 116.8, 115.5, 115.0, 64.3, 29.7 ppm. HRMS m/z: [M+H]+ calcd for C8H11ClNO
172.0524; found 172.0522.

Potassium O-ethyl carbonodithioate (2.60 g, 16.2 mmol) and 2-chloro-4-phenoxyaniline (3.28,
1.62 g, 7.37 mmol) were added to a 100 mL round bottomed flask containing a stir bar and
dissolved in 22 mL of DMF to give a brown solution. The mixture was heated with stirring at
120 °C for 16 h, and then cooled to room temperature. The reaction mixture was diluted with 80
of mL ice water and acidified with 25 mL of 2 M HCl. The mixture was stirred in an ice bath for
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several hours. The resulting precipitate was filtered and rinsed with warm 1:1
chloroform:hexane. The second solid was collected and dried to yield 3.31 (0.578 g, 30%) as a
red solid. 1H NMR (600 MHz, DMSO) δ 13.76 (br s, 1H), 7.4-7.5 (m, 3H), 7.31 (d, 1H, J=8.7
Hz), 7.15 (t, 1H, J=7.3 Hz), 7.10 (d, 1H, J=8.9 Hz), 7.02 (d, 2H, J=8.0 Hz) ppm. 13C NMR (151
MHz, DMSO) δ 190.0, 157.4, 153.9, 138.1, 131.4, 130.6, 124.0, 119.2, 118.8, 113.9, 112.7 ppm.
HRMS m/z: [M+H]+ calcd for C13H10NOS2 260.0198; found 260.0214.

Using conditions identical to those described above for compound 3.02, 3.31 (0.410 g, 1.58
mmol) was converted to 3.32 to yield tan crystals (0.417 g, 96%). 1H NMR (400 MHz, CDCl3) δ
7.78 (s, 1H), 7.3-7.4 (m, 3H), 7.1 (m, 2H), 7.0 (m, 2H), 2.76 (s, 3H) ppm. 13C NMR (101 MHz,
CDCl3) δ 166.7, 157.3, 154.2, 149.6, 136.3, 129.8, 123.4, 122.0, 118.8, 118.3, 110.6, 16.0 ppm.
HRMS m/z: [M+H]+ calcd for C14H12NOS2 274.0355; found 274.0372.

Using conditions identical to those described above for compound 3.03, 3.32 (0.417 g, 1.53
mmol) was converted to 3.33 to yield a yellow solid (0.474 g, 78%). 1H NMR (600 MHz,
CD2Cl2) δ 7.68 (d, 1H, J=9.1 Hz), 7.41 (br t, 2H, J=7.8 Hz), 7.1-7.2 (m, 2H), 7.0-7.1 (m, 2H),
4.1 (m, 2H), 3.96 (s, 3H), 1.19 (t, 3H, J=7.1 Hz) ppm. HRMS m/z: [M+H]+ calcd for
C19H17N2O2S3 401.0447; found 401.0458.
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Using conditions identical to those described above for compound 3.04, 3.33 (0.450 g, 1.12
mmol) was converted to 3.34 to yield a yellow solid (0.498 g, 75%). HRMS m/z: [M]+ calcd for
C20H19N2O2S3 415.0609; found 415.0607.

Using conditions identical to those described above for compound 3.06, 3.34 (0.396 g, 0.674
mmol) was converted to 3.35 to yield an orange solid (0.340 g, 79%). 1H NMR (600 MHz,
DMSO) δ 8.26 (d, 1H, J=4.0 Hz), 7.90 (br d, 1H, J=3.6 Hz), 7.6-7.7 (m, 2H), 7.42 (q, 4H, J=7.9
Hz), 7.3-7.4 (m, 3H), 7.23 (br d, 1H, J=8.7 Hz), 7.17 (br t, 1H, J=7.4 Hz), 7.03 (br d, 2H, J=8.0
Hz), 6.52 (s, 1H), 5.76 (s, 2H), 4.0-4.2 (m, 5H), 0.98 (br t, 3H, J=7.1 Hz) ppm. 13C NMR (151
MHz, DMSO) δ 163.9, 161.6, 157.5, 153.9, 153.6, 137.1, 135.7, 135.1, 130.6, 129.6, 128.9,
128.1, 127.9, 127.8, 124.1, 119.2, 118.7, 115.1, 114.0, 113.5, 83.8, 80.9, 53.5, 39.0, 35.4, 12.3
ppm. HRMS m/z: [M]+ calcd for C30H26N3O2S3 556.1187; found 556.1206.
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Potassium O-ethyl carbonodithioate (1.58 g, 9.83 mmol) and 2-chloro-4-methoxyaniline (3.29,
0.704 g, 4.47 mmol) were added to a 100 mL round bottomed flask containing a stir bar and
dissolved in 13 mL of DMF to give a brown solution. The mixture was heated with stirring at
120 °C for 2 days, and then cooled to room temperature. The reaction mixture was diluted with
40 mL of ice water and acidified with 15 mL of 2 M HCl. A few drops of 6 M HCl were added
to promote precipitation. The resulting precipitate was filtered and rinsed once with warm 1:1
chloroform:hexane. The second solid was collected and dried to yield 3.36 (0.278 g, 32%) as a
tan solid. 1H NMR (600 MHz, DMSO) δ 13.62 (br s, 1H), 7.36 (d, 1H, J=2.5 Hz), 7.22 (d, 1H,
J=9.1 Hz), 7.00 (dd, 1H, J=2.4, 8.9 Hz), 3.33 (br s, 3H) ppm.

13

C NMR (151 MHz, DMSO) δ

188.8, 157.1, 135.7, 131.2, 115.3, 113.6, 106.4, 56.2 ppm. HRMS m/z: [M+H]+ calcd for
C8H8NOS2 198.0042; found 198.0052.

Using conditions identical to those described above for compound 3.02, 3.36 (0.364 g, 1.84
mmol) was converted to 3.37 to yield tan crystals (0.245 g, 63%). 1H NMR (600 MHz, CDCl3) δ
7.78 (d, 1H, J=9.1 Hz), 7.2-7.3 (m, 1H), 7.03 (dd, 1H, J=2.5, 8.7 Hz), 3.88 (s, 3H), 2.80 (s, 3H)
ppm. 13C NMR (151 MHz, CDCl3) δ 164.9, 157.0, 148.0, 136.5, 121.9, 114.8, 104.2, 55.8, 16.0
ppm. HRMS m/z: [M+H]+ calcd for C9H10NOS2 212.0198; found 212.0213.
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Using conditions identical to those described above for compound 3.03, 3.37 (0.235 g, 1.11
mmol) was converted to 3.38 to yield a yellow solid (0.291 g, 77%). 1H NMR (600 MHz,
CD2Cl2) δ 7.2 (m, 2H), 7.05 (br d, 1H, J=9.1 Hz), 4.23 (q, 2H, J=6.7 Hz), 3.9 (m, 6H), 1.3 (m,
3H) ppm. 13C NMR (151 MHz, CD2Cl2) δ 165.5, 157.0, 154.0, 134.3, 127.7, 114.3, 111.5, 106.4,
83.9, 77.7, 56.0, 39.8, 34.5, 12.0 ppm. HRMS m/z: [M+H]+ calcd for C14H15N2O2S3 339.0290;
found 339.0306.

Using conditions identical to those described above for compound 3.04, 3.38 (0.200 g, 0.591
mmol) was converted to 3.39 to yield a yellow solid (0.241 g, 78%). 1H NMR (600 MHz,
DMSO) δ 7.93 (d, 1H, J=9.1 Hz), 7.81 (d, 1H, J=2.2 Hz), 7.47 (d, 2H, J=8.0 Hz), 7.28 (dd, 1H,
J=2.2, 9.1 Hz), 7.11 (d, 2H, J=7.6 Hz), 4.22 (s, 3H), 4.16 (br d, 2H, J=7.3 Hz), 3.8-3.9 (m, 3H),
3.05 (s, 3H), 2.29 (s, 3H), 1.32 (t, 3H, J=7.1 Hz) ppm.

C NMR (151 MHz, DMSO) δ 176.8,

13

162.9, 160.2, 158.0, 146.4, 138.0, 134.8, 128.5, 128.2, 126.0, 116.7, 115.3, 107.2, 85.8, 56.5,
42.9, 36.6, 21.2, 16.5, 12.3 ppm. HRMS m/z: [M]+ calcd for C15H17N2O2S3 353.0452; found
353.0467.
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Using conditions identical to those described above for compound 3.06, 3.39 (0.148 g, 0.281
mmol) was converted to 3.40 to yield an orange solid (0.137 g, 85%). 1H NMR (600 MHz,
DMSO) δ 8.24 (d, 1H, J=4.0 Hz), 7.87 (d, 1H, J=4.0 Hz), 7.62 (d, 1H, J=9.1 Hz), 7.60 (d, 1H,
J=2.5 Hz), 7.4 (m, 2H), 7.36 (d, 3H, J=8.0 Hz), 7.12 (dd, 1H, J=2.5, 9.1 Hz), 6.49 (s, 1H), 5.75
(s, 2H), 4.1 (m, 5H), 3.81 (s, 3H), 0.97 (t, 3H, J=7.1 Hz) ppm. 13C NMR (151 MHz, DMSO) δ
163.7, 161.5, 157.0, 156.9, 153.9, 135.6, 135.1, 134.7, 129.6, 128.9, 127.9, 127.7, 115.2, 114.8,
113.6, 107.1, 83.6, 80.3, 56.3, 53.5, 39.0, 35.3, 12.3 ppm. HRMS m/z: [M]+ calcd for
C25H24N3O2S3 494.1031; found 494.1050.

4-Bromo-2-chloroaniline (2.01 g, 9.72 mmol), 2,2,2-trifluoroethanol (3.66 mL, 48.5 mmol),
potassium carbonate (4.05 g, 29.3 mmol), CuI (0.0372 g, 0.195 mmol), Fe(acac)3 (0.518 mL,
0.750 M in DMF, 0.389 mmol) and 6 mL of DMF were added to a 50 mL screw cap reaction vial
containing a stir bar. The mixture was flushed with argon, sealed, and heated with stirring to 135
°C for 1 day, then allowed to cool to room temperature. The mixture was diluted with diethyl
ether and filtered over a pad of celite. The filtrate was washed with brine (3x). The combined
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organic layers were dried with sodium sulfate and concentrated on a rotary evaporator. The
residue was purified by flash column chromatography (15% DCM in hexanes) to yield 3.41
(0.871 g, 40%) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 6.90 (d, 1H, J=2.3 Hz), 6.7 (m,
2H), 4.24 (q, 2H, J=8.2 Hz), 3.84 (br s, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 150.2, 138.5,
119.6, 116.8, 116.5, 115.6, 67.4, 67.0 ppm. HRMS m/z: [M+H]+ calcd for C8H8ClF3NO
226.0241; found 226.0255.

Potassium

O-ethyl

carbonodithioate

(1.37

g,

8.52

mmol)

and

2-chloro-4-(2,2,2-

trifluoroethoxy)aniline (3.41, 0.871 g, 3.86 mmol) were added to a 50 mL round bottomed flask
containing a stir bar and dissolved in 12 mL of DMF to give a brown solution. The mixture was
heated with stirring at 120 °C for 16 h, and then cooled to room temperature. The reaction
mixture was diluted with 40 mL of ice water and acidified with 12 mL of 2 M HCl. The resulting
precipitate was filtered and rinsed with warm 1:1 chloroform:hexane. The second solid was
collected and dried to yield 3.42 (0.384 g, 38%) as a tan solid. 1H NMR (600 MHz, DMSO) δ
13.71 (br s, 1H), 7.48 (d, 1H, J=2.2 Hz), 7.25 (d, 1H, J=9.1 Hz), 7.13 (dd, 1H, J=2.4, 8.9 Hz),
4.7-4.8 (m, 2H) ppm. 13C NMR (151 MHz, DMSO) δ 189.4, 154.7, 136.9, 131.1, 115.9, 113.6,
108.2, 65.9, 65.6 ppm. HRMS m/z: [M+H]+ calcd for C9H7F3NOS2 265.9916; found 265.9929.
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Using conditions identical to those described above for compound 3.02, 3.42 (0.283 g, 1.07
mmol) was converted to 3.43 to yield tan crystals (0.255 g, 86%). 1H NMR (600 MHz, CDCl3) δ
7.72 (d, 1H, J=9.1 Hz), 7.24 (d, 1H, J=2.5 Hz), 6.99 (dd, 1H, J=2.5, 8.7 Hz), 4.33 (q, 2H, J=8.1
Hz), 2.71 (s, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 166.6, 154.6, 149.2, 136.4, 122.1, 115.2,
106.5, 66.9, 66.6, 16.0 ppm. HRMS m/z: [M+H]+ calcd for C10H9F3NOS2 280.0072; found
280.0091.

Using conditions identical to those described above for compound 3.03, 3.43 (0.249 g, 0.890
mmol) was converted to 3.44 to yield a yellow solid (0.209 g, 58%). 1H NMR (600 MHz,
CD2Cl2) δ 7.15 (s, 1H), 7.11 (br d, 1H, J=9.1 Hz), 7.00 (br d, 1H, J=8.7 Hz), 4.35 (q, 2H, J=8.0
Hz), 4.11 (q, 2H, J=7.3 Hz), 3.79 (s, 3H), 1.2 (m, 5H) ppm. HRMS m/z: [M+H]+ calcd for
C15H14F3N2O2S3 407.0164; found 407.0179.

Using conditions identical to those described above for compound 3.04, 3.44 (0.178 g, 0.438
mmol) was converted to 3.45 to yield a yellow solid (0.132 g, 51%). 1H NMR (600 MHz,
DMSO) δ 7.99 (d, 1H, J=9.1 Hz), 7.93 (d, 1H, J=2.5 Hz), 7.47 (d, 2H, J=8.0 Hz), 7.44 (dd, 1H,
J=2.5, 9.1 Hz), 7.11 (d, 2H, J=8.0 Hz), 4.90 (d, 2H, J=8.7 Hz), 4.23 (s, 3H), 4.17 (d, 2H, J=7.3
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Hz), 3.85 (s, 1H), 3.05 (s, 2H), 2.29 (s, 3H), 1.33 (t, 3H, J=7.3 Hz), 1.14 (s, 1H) ppm. HRMS
m/z: [M]+ calcd for C16H16F3N2O2S3 421.0326; found 421.0331.

Using conditions identical to those described above for compound 3.06, 3.45 (0.106 g, 0.179
mmol) was converted to 3.46 to yield an orange solid (0.110 g, 95%). 1H NMR (600 MHz,
DMSO) δ 8.25 (d, 1H, J=4.0 Hz), 7.89 (d, 1H, J=4.0 Hz), 7.7-7.8 (m, 2H), 7.4-7.5 (m, 2H), 7.37.4 (m, 3H), 7.28 (dd, 1H, J=2.5, 9.1 Hz), 6.5-6.6 (m, 1H), 5.76 (s, 2H), 4.84 (d, 2H, J=8.7 Hz),
4.0-4.2 (m, 5H), 0.98 (t, 3H, J=7.1 Hz) ppm.

13

C NMR (151 MHz, DMSO) δ 163.9, 161.6,

157.0, 154.4, 153.9, 136.0, 135.7, 135.1, 129.6, 128.9, 127.9, 127.7, 115.5, 115.0, 113.7, 109.0,
83.7, 80.7, 65.9, 53.5, 46.2, 39.0, 35.4, 12.3 ppm. HRMS m/z: [M]+ calcd for C26H23F3N3O2S3
562.0904; found 562.0927.

4-Bromo-2-chloroaniline (2.02 g, 9.80 mmol), benzyl alcohol (4.03 mL, 38.8 mmol), potassium
carbonate (2.69 g, 19.4 mmol), CuI (0.0442 g, 0.232 mmol), Fe(acac)3 (0.517 mL, 0.750 M in
DMF, 0.388 mmol) and 3.5 mL of DMF were added to a 50 mL screw cap reaction vial
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containing a stir bar. The mixture was flushed with argon, sealed, and heated with stirring to 135
°C for 1 day, then allowed to cool to room temperature. The mixture was diluted with diethyl
ether and filtered over a pad of celite. The filtrate was washed with brine (3x). The combined
organic layers were dried with sodium sulfate and concentrated on a rotary evaporator. The
residue was purified by flash column chromatography (30% DCM in hexanes) to yield 3.47
(0.576 g, 25%) as a brown oil. 1H NMR (600 MHz, CDCl3) δ 7.2-7.3 (m, 4H), 7.2 (m, 1H), 6.83
(d, 1H, J=2.9 Hz), 6.63 (br d, 1H, J=2.5 Hz), 6.6 (m, 1H), 4.85 (s, 2H), 3.5-3.8 (m, 2H) ppm. 13C
NMR (151 MHz, CDCl3) δ 151.8, 137.1, 137.1, 128.6, 128.0, 127.6, 119.8, 116.8, 116.1, 115.4,
71.0 ppm. HRMS m/z: [M+H]+ calcd for C13H13ClNO 234.0680; found 234.0685.

Potassium O-ethyl carbonodithioate (2.08 g, 13.0 mmol) and 4-(benzyloxy)-2-chloroaniline
(3.47, 1.38 g, 5.90 mmol) were added to a 50 mL round bottomed flask containing a stir bar and
dissolved in 18 mL of DMF to give a brown solution. The mixture was heated with stirring at
120 °C for 1 day, and then cooled to room temperature. The reaction mixture was diluted with 60
mL of ice water and acidified with 20 mL of 2 M HCl. The resulting precipitate was filtered and
rinsed with warm 1:1 chloroform:hexane. The second solid was collected and dried to yield 3.48
(0.509 g, 32%) as a tan solid. 1H NMR (600 MHz, DMSO) δ 13.63 (br s, 1H), 7.4-7.5 (m, 5H),
7.3-7.4 (m, 1H), 7.23 (d, 1H, J=9.1 Hz), 7.08 (dd, 1H, J=2.2, 9.1 Hz), 5.11 (s, 2H) ppm.

13

C

NMR (151 MHz, DMSO) δ 188.9, 156.1, 137.2, 135.9, 131.1, 128.9, 128.4, 128.3, 116.0, 113.6,
107.6, 70.4 ppm. HRMS m/z: [M+H]+ calcd for C14H12NOS2 274.0355; found 274.0365.
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Using conditions identical to those described above for compound 3.02, 3.48 (0.618 g, 2.26
mmol) was converted to 3.49 to yield tan crystals (0.598 g, 92%). 1H NMR (600 MHz, CDCl3) δ
7.67 (d, 1H, J=9.1 Hz), 7.3-7.4 (m, 4H), 7.2-7.3 (m, 1H), 7.21 (br d, 1H, J=2.2 Hz), 6.99 (dd,
1H, J=2.2, 8.7 Hz), 5.00 (s, 2H), 2.67 (s, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 165.1, 156.1,
148.2, 136.7, 136.4, 128.7, 128.1, 127.5, 121.9, 115.5, 105.6, 70.7, 16.1 ppm. HRMS m/z:
[M+H]+ calcd for C15H14NOS2 288.0511; found 288.0529.

Using conditions identical to those described above for compound 3.03, 3.49 (0.596 g, 2.07
mmol) was converted to 3.50 to yield a yellow solid (0.404 g, 47%). HRMS m/z: [M+H]+ calcd
for C20H19N2O2S3 415.0603; found 415.0628.

Using conditions identical to those described above for compound 3.04, 3.50 (0.385 g, 0.929
mmol) was converted to 3.51 to yield a yellow solid (0.375 g, 67%). 1H NMR (600 MHz,
DMSO) δ 7.93 (d, 1H, J=9.1 Hz), 7.90 (d, 1H, J=2.5 Hz), 7.4-7.5 (m, 6H), 7.4 (m, 1H), 7.3-7.4
89

(m, 1H), 7.10 (d, 2H, J=7.6 Hz), 5.21 (s, 2H), 4.21 (s, 3H), 4.16 (br d, 2H, J=7.3 Hz), 3.05 (s,
3H), 2.28 (s, 3H), 1.32 (t, 3H, J=7.3 Hz) ppm.

C NMR (151 MHz, DMSO) δ 176.9, 162.9,

13

160.2, 156.9, 146.4, 138.0, 136.9, 135.0, 129.0, 128.6, 128.5, 128.4, 128.2, 126.0, 117.2, 115.4,
108.4, 85.8, 70.5, 42.9, 36.6, 21.2, 16.6, 12.3 ppm. HRMS m/z: [M]+ calcd for C21H21N2O2S3
429.0760; found 429.0806.

Using conditions identical to those described above for compound 3.06, 3.51 (0.326 g, 0.543
mmol) was converted to 3.52 to yield a brick red solid (0.297 g, 84%). 1H NMR (600 MHz,
DMSO) δ 8.24 (d, 1H, J=4.4 Hz), 7.87 (d, 1H, J=4.0 Hz), 7.67 (d, 1H, J=2.5 Hz), 7.61 (d, 1H,
J=9.1 Hz), 7.3-7.5 (m, 10H), 7.18 (dd, 1H, J=2.5, 9.1 Hz), 6.48 (s, 1H), 5.74 (s, 2H), 5.14 (s,
2H), 4.0-4.1 (m, 5H), 0.97 (t, 3H, J=7.1 Hz) ppm. 13C NMR (151 MHz, DMSO) δ 163.7, 161.4,
156.8, 155.9, 153.8, 137.1, 135.6, 135.1, 134.9, 129.6, 128.9, 128.9, 128.5, 128.3, 127.9, 127.7,
115.7, 114.8, 113.6, 108.3, 83.6, 80.4, 70.4, 53.4, 39.0, 35.3, 12.3 ppm. HRMS m/z: [M]+ calcd
for C31H28N3O2S3 570.1338; found 570.1406.
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Imidazole (1 mol eq.) and potassium hydroxide (1.5 mol eq.) were added to a 100 mL round
bottomed flask containing a stir bar and dissolved in minimal DMSO. The mixture was heated
with stirring at 100 °C for 2 h, and then cooled 40 °C. Benzyl bromide (1 mol eq.) was added to
the reaction mixture and stirred for 2 h. The reaction mixture was cooled to room temperature
and diluted with 50 mL of ice water. The resulting precipitate was filtered and rinsed three times
with water. The solid was extracted with dichloromethane and concentrated in a rotary
evaporator to yield 3.55 as a white solid. If impure, the crude product is purified by flash column
chromatography (3:7 hexanes:ethyl acetate → 100% ethyl acetate). 1H NMR (400 MHz, CDCl3)
δ 7.52 (s, 1H), 7.3 (m, 2H), 7.13 (br d, 2H, J=6.4 Hz), 7.07 (s, 1H), 6.88 (s, 1H), 5.10 (s, 2H)
ppm.

Compound 3.55 (2.41 g, 15.2 mmol) was placed in a 100 mL round bottomed flask containing a
stir bar and the flask was placed in a high vacuum for drying with heat. The flask was then
cooled to room temperature, placed under an argon atmosphere, and sealed with a rubber septum.
20 mL of dry THF were injected into the reaction flask. The reaction was placed in a dry iceisopropanol bath for cooling at -78 °C. TMEDA (2.53 mL, 16.8 mmol) were injected into the
reaction. A solution of n-butyllithium (1.5 M in THF, 11.20 mL, 16.8 mmol) was injected
dropwise into the reaction with constant stirring. After addition, the reaction was stirred for 40
minutes. 1.77 mL of DMF were added at -78 °C, and the reaction was stirred for 10 minutes at
the same temperature, then warmed to room temperature to stir overnight. The reaction was
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quenched with saturated ammonium chloride and was extracted with ethyl acetate (3x). The
combined organic layers were dried with sodium sulfate and concentrated on a rotary evaporator.
The residue was purified by flash column chromatography (50% ethyl acetate in hexanes →
100% ethyl acetate) to yield 3.56 (1.20 g, 42%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
9.84 (s, 1H), 7.3-7.4 (m, 5H), 7.2 (m, 2H), 7.13 (s, 1H), 5.61 (s, 2H) ppm. 13C NMR (101 MHz,
CDCl3) δ 182.2, 143.3, 135.7, 131.9, 129.0, 128.3, 127.7, 126.2, 50.9 ppm.

Compound 3.56 (1.20 g, 6.46 mmol) was placed in a 100 mL round bottomed flask containing a
stir bar and dissolved in 12 mL of ethanol. The reaction was cooled to 0 °C, and then sodium
borohydride was added (0.248 g, 6.55 mmol). The reaction was stirred for 6 h at room
temperature. The ethanol was removed on a rotary evaporator, and the residue was diluted with
water and saturated ammonium chloride, then extracted with ethyl acetate (3x). The combined
organic layers were dried with sodium sulfate and concentrated on a rotary evaporator. The
residue was purified by flash column chromatography (3:1 ethyl acetate:hexanes → 100% ethyl
acetate) to yield 3.57 (0.843 g, 69%) as a clear-yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.37.4 (m, 3H), 7.15 (br d, 2H, J=7.5 Hz), 6.95 (s, 1H), 6.85 (s, 1H), 5.22 (s, 2H), 4.65 (s, 2H), 3.66
(br s, 1H) ppm. 13C NMR (101 MHz, CDCl3) δ 147.7, 136.1, 128.9, 128.1, 127.1, 127.0, 120.7,
56.2, 49.7 ppm.
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Compound 3.57 (0.158 g, 0.839 mmol) was dissolved in 4 mL of dry THF in a 10 mL round
bottomed flask containing a stir bar. The reaction was placed under an argon atmosphere and
cooled to 0 °C by placing in an ice water bath. PBr3 (0.040 mL, 0.42 mmol) was added dropwise
via syringe, and the reaction mixture was stirred for 1 h at 0 °C. The reaction was quenched with
saturated NaHCO3 added dropwise and stirred for 5 minutes. Et2O was added, then the organic
layer was decanted, and the mixture was washed with further saturated NaHCO3. The organic
fractions were dried with Na2SO4 and concentrated on a rotary evaporator to yield 3.58 (0.049 g,
23%) as a yellow oil that was used without further purification.
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Chapter 4
Pentamidine Analog for Treatment of Infectious Tropical Diseases
4.1 Pentamidine and its Uses
Pentamidine is composed of two benzamidine containing rings ether-linked through a pentane
linker (Figure 4.1). It is used as a stand-alone or combination treatment for multiple infectious
diseases.1 It was discovered in the 1940s as an antiprotozoal for leishmaniasis and
trypanosomiasis.1 Its antifungal effects were demonstrated in 1987 against Pneumocystis
pneumonia in HIV patients.1-2 Pentamidine is currently classified as an orphan drug by the FDA.3
It is a diamidine, which carries a +2 charge at physiological pH. Due to its basic properties, it is
easily protonated in neutral conditions and therefore also under the acidic conditions of the
stomach. The amidine functional groups are easily hydrolyzed and the drug loses its active
properties.1

Figure 4.1 Structure of Pentamidine
Pentamidine has less than ideal pharmacokinetic properties.1 It is not orally bioavailable due to
hydrolysis, so it requires intravenous (IV) or intramuscular (IM) administration.1,

4

When

administered through a nebulizer, it can accumulate in the lungs.1 Pentamidine binds to tissues
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and plasma proteins; the liver is the major organ for accumulation.1 It can cross the blood-brain
barrier, but it does not reach the cerebrospinal fluid in large quantities.1 It is metabolized by
cytochrome P450 in the liver.1 The half-life of pentamidine is 5-8 hours with IV administration
and 7-11 hours with IM administration.1 It can remain in the body for as long as 8 months.1
The mechanism of action for pentamidine is not fully known. It is thought to interfere with DNA,
RNA, phospholipid, and protein synthesis.1 Pentamidine binds to adenine-thymine rich regions
in mitochondrial kinetoplast DNA found in trypanosomes.1 It forms cross-links between two
adenine structures 4-5 bases apart. Nuclear DNA appears to be a secondary target.1
Pentamidine contains a host of limitations that prevent it from being a more widely distributed
drug. Some of the side effects include: diabetes mellitus, hypoglycemia, nausea, vomiting,
burning pain, hypotension, difficulty breathing and swallowing, kidney toxicity, myocarditis,
leukopenia, and thrombopenia.1,

4-5

These side effects are significant enough to cause further

hospitalization or even death. It is also not recommended for early pregnancy. Pentavalent
antimonial drugs act against multiple species of Leishmania, whereas pentamidine is limited to a
few species.4 Overall, most of the drugs used to treat leishmaniasis don’t act against the entire
spectrum of Leishmania parasites. The combination of treatments provides some solution to this
problem. It further reduces the likelihood of treatment failure and drug resistance.
4.2 Modification of Pentamidine
As mentioned above, pentamidine does not have optimal pharmacokinetic properties as a drug
and is a good target for modification. Previous research has focused on either changing the
pentane linker or making modifications to the phenyl rings on either side of the molecule.
Because it is hypothesized that pentamidine binds to DNA, strongly basic and nucleophilic
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functional groups on either end are desired. Aliphatic groups are disfavored in medicinal
chemistry due to plasma protein binding and therefore limiting distribution of the drug in the
body. Research has been done on rigidifying the pentane chain with an aromatic ring system;
such a change has not shown to improve activity significantly.

Figure 4.2 Isoquinoline Analog of Pentamidine
The goal of our research is to make a change to one of the amidine groups in pentamidine to
improve its stability. Our goal is to cyclize one of the amidine groups into its adjacent phenyl
ring in the form of an isoquinoline ring system as shown in Figure 4.2. An amino isoquinoline
remains a basic group that should have similar properties when interacting with target molecules.
The main difference is that an isoquinoline would not be prone to hydrolysis like a benzamidine
would. Herein are described the steps taken to synthesize an isoquinoline analog of pentamidine.
4.3 Initial Synthetic Routes
We started the synthesis of this isoquinoline analog of pentamidine through a linear synthetic
route. We began with the linker portion, 1,5-pentanediol, and mono-protected one alcohol to
make 4.01, as shown in Scheme 4.1.6 This allowed us to work on the other side of the molecule
to build up the isoquinoline ring. Additionally, the use of sodium hydride was required to prevent
the double protection of the pentane linker. The alcohol in 4.01 was made into a leaving group
by converting it into tosylate 4.02 to set it up for displacement by 3-hydroxybenzaldehyde and
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create compound 4.03.7 Next, the aldehyde was subjected to a Knoevenagel condensation to set
the α,β-unsaturated carboxylic acid 4.04.8

Scheme 4.1 First Half of Synthetic Route 1
The carboxylic acid was activated using methyl chloroformate to create the mixed anhydride
4.05 (Scheme 4.2).9 Making an acyl chloride was not successful due to rapid hydrolysis, and the
anhydride proved to be a much more stable compound. Although it was treated as a reactive
intermediate, structural proof of the formation of the anhydride was possible by 1H NMR. The
anhydride was then subjected to an acyl transfer reaction using sodium azide to create acyl azide
4.06.10 The acyl azide was slowly heated to promote thermal decomposition and cause the
leaving of nitrogen gas for the formation of the acyl nitrene. This underwent a Curtius
rearrangement to form an isocyanate, which then was heated further with catalytic iodine to aid
in alkene isomerization. A heat-promoted Friedel-Crafts acylation on the isocyanate generated
isocarbostyril 4.07.10
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Scheme 4.2 Second Half of Synthetic Route 1
The next step in this synthetic route was the removal of the benzyl protecting group to work on
the other side of the pentane linker, shown in Scheme 4.3. Compound 4.07 was subjected to
reductive conditions using hydrogen gas and palladium on carbon, but the benzyl group could
not be removed. Instead, the alkene in the isocarbostyril ring was reduced to form 4.09; it was
detected by LRMS with a mass difference of +2 when compared to the mass of 4.07. Different
sources of hydrogen and different palladium catalysts were used in an attempt to synthesize 4.08.
The use of ammonium formate as a hydrogen source in the presence of palladium on carbon and
the use of palladium hydroxide both proved ineffective in removing the benzyl group.
Additionally, Lewis acid conditions were also used following literature procedures.11 Iron (III)
chloride was added to 4.07 under inert conditions, however only trace product 4.08 was detected.
Ultimately, due to the inability to remove the benzyl protecting group, this particular synthetic
route was abandoned.
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Scheme 4.3 Attempted Deprotection Conditions
A similar route was started using a p-methoxybenzyl (PMB) protecting group instead (Scheme
4.4). This new protecting group typically can be removed under oxidative conditions using DDQ,
therefore, it would not be subjected to the difficulties encountered in the first synthetic route. pMethoxybenzyl bromide was prepared according to literature conditions.12 1,5-Pentanediol was
again mono-protected using similar conditions described previously to make compound 4.11.13
The rest of the route up to the point of the formation of the acyl azide was successfully
performed under identical conditions as the benzyl group route. The acyl azide was further
treated under the same conditions as the reaction for 4.07 in order to create compound 4.17, but
the reaction did not proceed as expected. This reaction created multiple unknown side products,
many of which looked like the result of decomposition of the starting material. One potential
reason why this reaction did not yield the desired products stems from the activation
requirements for a Friedel-Crafts acylation. Acylation occurs on an activated aromatic ring
system, and compound 4.16 contains two activated rings. It is possible that the ring in the pmethoxybenzyl ether is more activated due to the two oxygen atoms attached, thus donating
greater electron density to this ring. Although the reaction was done under dilute conditions to
promote an intramolecular reaction, the ring from the protecting group was within close range
for the isocyanate to add on a different position and not form the desired isocarbostyril.
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Scheme 4.4 Synthetic Route 2
In order to get around problems with protecting groups containing aromatic rings, a new
synthetic route was devised using a silyl protecting group. This third synthetic route (Scheme
4.5) was performed once again starting with 1,5-pentanediol and mono-protecting one of the
alcohols with a tert-butyldimethylsilyl (TBS) group using TBS chloride. Similar conditions for
mono-protection were performed to create compound 4.18.14 The proceeding steps were
successfully carried out in a similar manner to the previous two synthetic routes. With the
formation of acyl azide 4.23, the next reaction to form the desired isocarbostyril 4.24 was not
successful.

Scheme 4.5 Synthetic Route 3
Similar to the route involving the PMB protecting group, it was evident from this reaction that
multiple degraded byproducts were present. Due to multiple synthetic routes failing at a similar
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point, it was hypothesized that the particular protecting group was not the problem, and rather it
was the large linker portion attached to the ring system undergoing the Friedel-Crafts acylation.
To test this hypothesis, we used a model system with the linker portion cropped to optimize
conditions for the isocarbostyril. This model system was used directly in the new route as part of
a convergent synthesis.
4.4 Convergent Synthetic Route
We decided to have a model system to improve synthetic yields for the isocarbostyril compound.
This model system resulted in excellent yields compared to the previous synthetic routes with the
pentane linker attached. We envisioned turning this model system into the actual synthetic route
by forming the isocarbostyril first and attaching the linker at a later step. The idea was that a
benzonitrile and the isocarbostyril in advanced intermediate 4.25 could simultaneously be
converted into a benzamidine and an amino isoquinoline, respectively. As shown in Scheme 4.6,
this route required that we synthesize compounds 4.26 and 4.27 separately as the two pieces for
the convergent synthesis of 4.25.

Scheme 4.6 Convergent Route Retrosynthesis
We started with 3-hydroxybenzaldehyde and methylated the phenol to form aldehyde 4.28,15
shown in Scheme 4.7. This compound was then subjected to the standard Knoevenagel
condensation conditions described previously to create compound 4.29.8 The carboxylic acid was
activated using methyl chloroformate to make 4.30,9 and then reacted with sodium azide to make
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acyl azide 4.31.16 From there, compound 4.31 was slowly heated, then heated to a reflux in odichlorobenzene with catalytic iodine to make isocarbostyril 4.32 in 52% yield.10 This was a
great improvement over the first synthetic route with the benzyl protecting group. Compound
4.31 was then demethylated with 6 M HCl in a microwave reactor to generate 4.27 as the first
portion to make the desired advanced intermediate.17

Scheme 4.7 Synthesis of Isocarbostyril for the Convergent Route
The other portion for the convergent synthesis involved making 4.26, which included the pentane
linker for our desired pentamidine analog (Scheme 4.8). We started with mono-protecting 1,5pentanediol with a TBS protecting group as described previously to make compound 4.18. The
next step was to link this primary alcohol with 4-hydroxybenzonitrile in a Mitsunobu reaction
and form 4.33.18 The TBS group was removed using tetrabutylammonium fluoride (TBAF) to
create primary alcohol 4.34.19 An attempt to use another Mitsunobu reaction to link 4.34 and
4.27 was unsuccessful, so we converted 4.34 into tosylate 4.26 so it could be displaced by 4.27.
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Advanced intermediate 4.25 was made with poor yields (Scheme 4.10) but nevertheless with
greater overall success than with a linear synthetic route. Additionally, a byproduct matching the
mass of the addition of two equivalents of linker 4.26 onto isocarbostyril 4.27 was detected. This
prompted the optimization of this reaction using 4.26 as the limiting reactant to avoid adding
twice to the isocarbostyril.

Scheme 4.8 Synthesis of Linker Portion for the Convergent Route
In order to perform the final steps to make the isoquinoline analog of pentamidine from 4.25, we
employed the use of model systems once more to avoid wasting a valuable product while testing
reaction conditions, shown in Scheme 4.9. Isocarbostyril 4.32 was used as a model system for
conversion into its corresponding amino isoquinoline. It was first reacted with phosphorous
oxychloride to make chloroisoquinoline 4.35.20 Initial attempts to displace the chloride with
ammonia were unsuccessful. Benzylamine was used as a nucleophile instead to make the Nbenzylamino isoquinoline 4.36.21 The benzyl protecting group was removed under catalytic
reductive conditions and using ammonium formate as the source of hydrogen. Upon heating in a
sealed reaction vial for several days, the desired amino isoquinoline 4.37 was made and isolated
albeit in poor yields. Further optimization of this reaction was not done; however, the use of
increased pressure and temperature was considered.
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Scheme 4.9 Model Systems to Test Last Synthetic Steps
A separate model system was examined using on 4-bromobenzonitrile to test conditions on the
conversion of a nitrile to an amidine. This was done by reacting with ammonium chloride and
liquid ammonia in a sealed vessel in order to heat the liquid ammonia.22 Initially, typical screwcap reaction vials commonly found in synthetic labs proved unsuccessful in containing liquid
ammonia. The use of a bomb reactor was employed, yet it also easily leaked ammonia once it
was warmed past room temperature. Ultimately, a culture vial with a phenolic screw cap with
rubber liner proved to be the only type of vessel that permitted the containment of ammonia
under heated conditions. This reaction vial was charged with the benzonitrile and heated
overnight with liquid ammonia and ammonium chloride to form amidine 4.38.
The same set of steps done on the model system was performed on our advanced intermediate
4.25, shown in Scheme 4.10. 4.25 was converted to the chloroisoquinoline 4.39 in good yields.20
The next step was to have the benzylamine displacement to create compound 4.40.
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Scheme 4.10 Convergence of Two Portions and Setup for Final Steps
The last steps remaining to create the desired final product involved converting the nitrile to an
amidine and removing the benzyl group. Either step could have been tested first, although ideally
one route may have provided a better yield over the other (Scheme 4.11). The first reaction to be
tested was the conversion of the nitrile 4.40 to the corresponding amidine in liquid ammonia.22
The reaction was sealed and heated for one day at 60 °C to mimic the model system, and cooled
to -78 °C to check reaction progress by mass spectrometry. The reaction was heated slightly
more each day until significant formation of product could be detected.

Scheme 4.11 Two Potential Routes to Final Product
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One of the first byproducts that was detected was the formation of chloroisoquinoline 4.39. It is
possible that chloride from the ammonium chloride could have displaced the benzylamine from
the isoquinoline ring. Further heating at higher temperatures caused the formation of byproduct
4.44 by day 5 of heating (Figure 4.3). This was an interesting finding due to methanol now
adding to the isoquinoline ring. We do not believe it possible for methanol alone to have
displaced benzylamine, and rather went through the chloroisoquinoline intermediate. Further
proof of this hypothesis is the disappearance of compound 4.39 from the reaction mixture. A
trace amount of the desired final product 4.43 was also detected and characterized. There was
now some evidence for a small nucleophile to displace the chloride in the chloroisoquinoline, so
this suggested that it was possible to make the amino isoquinoline directly from
chloroisoquinoline 4.39. This finding supported the idea that there is a specific energy barrier
that must be reached for ammonia to act as nucleophile to displace the chloride; this energy
barrier had never been reached previously due to reaction vessels leaking ammonia before it
could get heated further. Ironically, this reaction yielded only trace amounts of the intended
amidine 4.41, and the starting material was largely recovered from the reaction mixture.

Figure 4.3 Intended Product and Byproducts Identified
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Scheme 4.12 Final Reaction for Isoquinoline Analog of Pentamidine
In order to finally synthesize our desired isoquinoline analog of pentamidine, we decided to take
compound 4.39 and directly subject it to reaction conditions described above (Scheme 4.12).22
This allowed us to simultaneously make two transformations in a single synthetic step and create
the desired final product. An initial run of this reaction showed the formation of an ion that
matches that of 4.43 in the form of [M+2H]2+/2 = 183. Seven days of heating for the previous
reaction proved to not be enough for full conversion of the starting material to product (or
byproducts), so this reaction is currently undergoing temperature and time optimizations for
maximum conversion to the pentamidine analog 4.43.
4.5 Conclusions
The synthesis of the isoquinoline analog of pentamidine was originally considered as a linear
synthesis with the goal of making the basic amino and amidine groups in the last step. The use of
protecting groups with the linker proved problematic when building up the isocarbostyril group.
In the end, the simplest route turned out to be the best route. The use of a convergent synthesis in
medicinal chemistry is favorable as it often provides a higher overall yield. In this synthesis, we
employed a convergent synthesis as the best approach to synthesize the isocarbostyril portion of
the molecule. It is our hope that this analog can be tested in biological assays against parasitic
microorganisms. We wish to compare this compound with pentamidine in terms of activity,
stability, and cytotoxicity, as well as with miltefosine, the current standard of care.
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4.6 Experimental Procedures

1,5-Pentanediol (6.03 g, 57.9 mmol) was dissolved in 90 mL of dry THF in a 250 mL round
bottomed flask containing a stir bar. NaH (60% in mineral oil, 2.43 g, 60.8 mmol) was added to
the solution in portions and it was allowed to stir at room temperature for 10 min. Benzyl
bromide (2.74 mL, 23.0 mmol) was dissolved in 5 mL dry THF and added dropwise to the
reaction. The reaction was heated with stirring to 70 °C for 28 h and then cooled to room
temperature to give a cream-colored suspension. The reaction was quenched by adding water
dropwise, and then the mixture was diluted in Et2O and washed with brine. The organic layer
was dried with MgSO4 and concentrated on a rotary evaporator. The residue was purified by
flash column chromatography (1:1 hexanes:ethyl acetate) to yield 4.01 (4.06 g, 91%) as a clear
oil. 1H NMR (400 MHz, CDCl3) δ 7.31 (m, 4H), 7.2-7.3 (m, 1H), 4.48 (s, 2H), 3.62 (t, 2H, J=1.0
Hz), 3.47 (t, 2H, J=1.0 Hz), 1.5-1.7 (m, 4H), 1.4-1.5 (m, 2H) ppm. 13C NMR (101 MHz, CDCl3)
δ 138.5, 128.3, 127.6, 127.5, 72.9, 70.3, 62.8, 32.5, 29.4, 22.4 ppm. HRMS m/z: [M+H]+ calcd
for C12H19O2 195.1380; found 195.1379.

Compound 4.01 (2.86 g, 14.7 mmol) was dissolved in 28 mL of DCM in a 100 mL round
bottomed flask containing a stir bar. Et3N (3.08 mL, 22.1 mmol), tosyl chloride (3.10 g, 16.3
mmol), and DMAP (0.184 g, 0.150 mmol) were added to the reaction mixture and it was stirred
at room temperature for 16 h. 100 mL DCM were added to the reaction mixture, and it was then
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washed with aqueous NaHCO3 (1x), water (1x), and brine (1x). The organic fractions were dried
with MgSO4 and concentrated on a rotary evaporator. The residue was purified by flash column
chromatography (10-40% ethyl acetate in hexanes) to yield 4.02 (4.12 g, 80%) as an orange oil.
1

H NMR (500 MHz, CDCl3) δ 7.78 (d, 2H, J=8.3 Hz), 7.2-7.4 (m, 7H), 4.47 (s, 2H), 4.02 (t, 2H,

J=6.4 Hz), 3.42 (t, 2H, J=6.4 Hz), 2.44 (s, 3H), 1.6-1.7 (m, 2H), 1.5-1.6 (m, 2H), 1.4-1.5 (m, 2H)
ppm. 13C NMR (126 MHz, CDCl3) δ 144.6, 138.5, 133.2, 129.8, 128.4, 127.9, 127.6, 127.5, 72.9,
70.5, 69.9, 29.1, 28.6, 22.2, 21.6 ppm.

Compound 4.02 (3.61 g, 10.4 mmol), 3-hydroxybenzaldehyde (1.43 g, 11.7 mmol), and
potassium carbonate (2.53 g, 18.3 mmol) were dissolved in 20 mL of acetonitrile in a 100 mL
round bottomed flask containing a stir bar to give a tan solution. The mixture was heated with
stirring to a reflux for 16 h. Upon cooling, the mixture was diluted with 50 mL Et 2O. The
mixture was filtered; the filtrate was concentrated on a rotary evaporator to give a brown oil. The
crude residue was purified by flash column chromatography (10-25% ethyl acetate in hexanes) to
yield 4.03 (2.76 g, 89%) as a yellow oil. 1H NMR (500 MHz, CDCl3) 9.97 (s, 1H), 7.4-7.5 (m,
2H), 7.38 (d, 1H, J=2.0 Hz), 7.3-7.4 (m, 3H), 7.28 (d, 1H, J=4.4 Hz), 7.16 (br d, 1H, J=6.8 Hz),
4.51 (s, 2H), 4.02 (t, 2H, J=6.6 Hz), 3.51 (t, 2H, J=6.4 Hz), 1.8-1.9 (m, 2H), 1.7-1.8 (m, 2H),
1.58 (br t, 2H, J=8.1 Hz) ppm. 13C NMR (126 MHz, CDCl3) 192.2, 159.6, 138.5, 137.8, 130.0,
128.4, 127.6, 127.5, 123.3, 121.9, 112.8, 72.9, 70.2, 68.1, 29.5, 29.0, 22.8 ppm. HRMS m/z:
[M+H]+ calcd for C19H22O3 299.1642; found 299.1640.
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Compound 4.03 (2.59 g, 8.68 mmol), malonic acid (3.64 g, 35.0 mmol), and piperidine (0.579
mL, 5.84 mmol) were added to a 100 mL round bottomed flask containing a stir bar. 35 mL of
pyridine were added, and the mixture was heated to a reflux for 6 h. Upon cooling, the reaction
mixture was poured into a 1 L Erlenmeyer flask containing 100 mL of 2 M HCl and was left to
stir in an ice water bath for 1 h. The resulting precipitate was collected by vacuum filtration and
washed with cold 1 M HCl to yield 4.04 (2.92 g, 99%) as a white solid. 1H NMR (400 MHz,
CDCl3) δ 7.72 (d, 1H, J=15.6 Hz), 7.33 – 7.28 (m, 6H), 7.11 (d, 1H, J=7.4 Hz), 7.0-7.1 (m, 1H),
6.93 (dd, 1H, J=2.0, 7.8 Hz), 6.42 (d, 1H, J=16.0 Hz), 4.50 (s, 2H), 3.97 (t, 2H, J=6.4 Hz), 3.50
(t, 2H, J=6.4 Hz), 2.45 (br s, 1H), 1.83 (m, 2H), 1.69 (m, 2H), 1.5-1.6 (m, 2H) ppm.

13

C NMR

(126 MHz, CDCl3) δ 179.1, 159.4, 146.9, 138.5, 135.4, 129.9, 128.4, 127.6, 127.5, 120.9, 117.4,
117.1, 113.7, 72.9, 70.2, 67.9, 29.5, 29.0, 22.8 ppm. HRMS m/z: [M+H]+ calcd for C21H25O4
341.1747; found 341.1752.

Carboxylic acid 4.04 (1.32 g, 3.88 mmol) was placed in a 100 mL round bottomed flask
containing a stir bar. It was dissolved in 12 mL of Et2O, and then Et3N (0.541 mL, 3.88 mmol)
was added. The flask was flushed with argon, sealed with a rubber septum, placed in an ice water
bath, and allowed to stir for 5 min. Methyl chloroformate (0.320 mL, 4.13 mmol) was added
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dropwise via syringe over 5 minutes. The reaction was stirred at 0 °C for 45 minutes, then it was
quenched with 1 mL of 0.1 M HCl. The resulting organic layer was separated and washed with
additional 0.1 M HCl solution (1x), saturated NaHCO3 (1x), and brine (1x). The organic
fractions were dried with Na2SO4 and concentrated on a rotary evaporator to yield 4.05 (1.47 g,
95%) as a brown oil that was used without further purification. 1H NMR (500 MHz, CDCl3) δ
7.79 (d, 1H, J=15.7 Hz), 7.3-7.4 (m, 6H), 7.12 (d, 1H, J=7.8 Hz), 7.0-7.1 (m, 1H), 7.0 (m, 1H),
6.40 (d, 1H, J=15.7 Hz), 4.51 (s, 2H), 4.0 (m, 2H), 3.95 (s, 3H), 3.51 (t, 2H, J=6.4 Hz), 1.8 (m,
2H), 1.7 (m, 2H), 1.5-1.6 (m, 2H) ppm.

C NMR (126 MHz, CDCl3) δ

13

13

C NMR

(CHLOROFORM-d, 126 MHz) δ 160.8, 159.5, 149.9, 149.3, 138.5, 134.8, 130.0, 128.4, 127.6,
127.5, 121.2, 117.8, 115.4, 113.9, 72.9, 70.2, 68.0, 55.9, 29.5, 29.0, 22.8 ppm.

Compound 4.05 (1.45 g, 3.65 mmol) was dissolved with 7 mL of dioxane in a 100 mL round
bottomed flask containing a stir bar. The reaction mixture was placed in an ice water bath. A
solution of NaN3 (0.296 g, 4.56 mmol) in 1.4 mL of water was added dropwise over 10 min to
the reaction mixture. The reaction was stirred with constant cooling at 0 °C for 1 h. The reaction
mixture was then poured over ice, extracted with ethyl acetate, and washed with saturated
NaHCO3. The organic layer was dried with Na2SO4 and concentrated on a rotary evaporator with
no heat to yield 4.06 (1.47 g, 90%) as a yellow oil that was used without further purification. 1H
NMR (500 MHz, CDCl3) 7.71 (d, 1H, J=15.7 Hz), 7.3-7.4 (m, 6H), 7.11 (d, 1H, J=7.3 Hz), 7.07.1 (m, 1H), 6.96 (dd, 1H, J=2.4, 8.3 Hz), 6.41 (d, 1H, J=15.7 Hz), 4.52 (s, 2H), 4.0 (m, 2H),
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3.52 (t, 2H, J=6.4 Hz), 1.8-1.9 (m, 2H), 1.7 (m, 2H), 1.5-1.6 (m, 2H) ppm. .

13

C NMR (126

MHz, CDCl3) δ 172.0, 159.5, 146.7, 138.5, 135.1, 130.0, 128.4, 127.6, 127.5, 121.2, 119.2,
117.5, 113.9, 72.9, 70.2, 68.0, 29.5, 29.0, 22.8 ppm.

Compound 4.06 (1.40 g, 3.83 mmol) was dissolved in 15 mL of o-dichlorobenzene in a 100 mL
round bottomed flask containing a stir bar. The reaction mixture was heated slowly to 75 °C by
increasing by 10 °C every 20-30 minutes, and then heated at 75 °C for 3 h. Catalytic I2 (one
small crystal) was added to the reaction and then heated at 180 °C overnight. The mixture was
cooled to room temperature. The solvent was removed by high vacuum distillation at 90 °C to
give a brown residue. The crude residue was purified by flash column chromatography (40%
ethyl acetate in hexanes - 100% ethyl acetate) to yield 4.07 (0.336 g, 26%) as a tan solid. 1H
NMR (400 MHz, CDCl3) δ 9.7-9.9 (m, 1H), 8.29 (d, 1H, J=9.0 Hz), 7.3-7.4 (m, 6H), 7.0-7.1 (m,
2H), 6.9 (m, 1H), 6.41 (d, 1H, J=8.1 Hz), 4.5 (m, 2H), 4.0-4.1 (m, 2H), 3.50 (t, 2H, J=6.2 Hz),
1.8-1.9 (m, 2H), 1.69 (br d, 2H, J=8.2 Hz), 1.6 (m, 2H) ppm. HRMS m/z: [M+H]+ calcd for
C21H24NO3 338.1751; found 338.1750.

117

Compound 4.07 (0.20 g, 0.59 mmol) was dissolved in 10 mL of methanol in a 25 mL round
bottomed flask containing a stir bar. Catalytic 10% w/w palladium on carbon (3.1 mg, 0.03
mmol) was added, then the reaction was sealed was purged by vacuum, then treated with
atmospheric hydrogen. Reaction was stirred for various days but did not yield the desired
product 4.08, instead yielding the reduced byproduct 4.09. LRMS m/z: [M+H]+ = 340.

Compound 4.07 (0.19 g, 0.56 mmol) was dissolved in 10 mL of dichloromethane in a 25 mL
round bottomed flask containing a stir bar. FeCl3 (0.42 g, 2.5 mmol) was added to the reaction
mixture and the flask was placed under an argon atmosphere. It was stirred for 4 hours and then
quenched with water. The mixture was extracted with CHCl3 and washed with brine. The organic
layers were Na2SO4 and concentrated on a rotary evaporator. The reaction did not yield the
desired product 4.08.

(4-Methoxyphenyl)methanol (5.00 g, 36.2 mmol) was dissolved in 100 mL of dry Et2O in a 250
mL round bottomed flask containing a stir bar. The reaction was placed under an argon
atmosphere and cooled to 0 °C by placing in an ice water bath. PBr3 (1.7 mL, 18 mmol) was
added dropwise via syringe, and the reaction mixture was allowed to stir for 2 h. It was quenched
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with saturated NaHCO3 added dropwise, then allowed to stir for 5 minutes. The mixture was
poured onto an Erlenmeyer flask containing saturated NaHCO3 and ice. The organic layer was
separated and washed with additional saturated NaHCO3, and then the organic fractions were
dried with MgSO4 and concentrated on a rotary evaporator to yield 4.10 (7.12 g, 98%) as a clear
oil that was used without further purification. 1H NMR (400 MHz, CDCl3) δ 7.3 (m, 2H), 6.8-6.9
(m, 2H), 4.49 (s, 2H), 3.79 (s, 2H) ppm.

NaH (60% in mineral oil, 2.88 g, 72.0 mmol) was suspended in 40 mL of dry THF in a 250 mL
round bottomed flask in an ice water bath and containing a stir bar. 1,5-Pentanediol (3.65 g, 35.1
mmol) was dissolved in 10 mL of dry THF and added dropwise to the reaction mixture and
allowed to stir for 1 h. Bu4NI (0.664 g, 1.79 mmol) was added, then 4.10 (7.12 g, 35.4 mmol)
was dissolved in 5 mL of dry THF and added dropwise to the reaction. The reaction stirred at
room temperature overnight, and then quenched with water. The mixture was further diluted in
water and extracted with ethyl acetate (3x 50 mL). The organic layers were dried with Na2SO4
and concentrated on a rotary evaporator. The residue was purified by flash column
chromatography (20% ethyl acetate in hexanes - 100% ethyl acetate) to yield 4.11 (4.17 g, 53%)
as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.2-7.3 (m, 2H), 6.8-6.9 (m, 2H), 4.41 (s, 2H), 3.78
(s, 3H), 3.62 (t, 2H, J=6.6 Hz), 3.43 (t, 2H, J=6.4 Hz), 1.5-1.6 (m, 4H), 1.4-1.5 (m, 2H) ppm.
HRMS m/z: [M+Na]+ calcd for C13H20O3Na 247.1305; found 247.1308.
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Using conditions identical to those described above for compound 4.02, 4.11 (4.30 g, 19.2 mmol)
was converted to 4.12 to yield a yellow oil (5.48 g, 75%). 1H NMR (500 MHz, CDCl3) δ 7.78 (d,
2H, J=8.3 Hz), 7.33 (d, 2H, J=7.8 Hz), 7.23 (d, 2H, J=8.8 Hz), 6.8-6.9 (m, 2H), 4.40 (s, 2H),
4.01 (t, 2H, J=6.6 Hz), 3.80 (s, 3H), 3.39 (t, 2H, J=6.4 Hz), 2.44 (s, 3H), 1.6-1.7 (m, 2H), 1.5-1.6
(m, 2H), 1.4 (m, 2H) ppm.

13

C NMR (126 MHz, CDCl3) δ 159.1, 144.6, 133.1, 130.5, 129.8,

129.2, 127.9, 113.8, 72.6, 70.5, 69.6, 55.3, 29.1, 28.6, 22.2, 21.6 ppm.

Using conditions identical to those described above for compound 4.03, 4.12 (5.48 g, 14.5 mmol)
was converted to 4.13 to yield a clear oil (3.65 g, 77%). 1H NMR (500 MHz, CDCl3) δ 9.97 (s,
1H), 7.3-7.5 (m, 3H), 7.2-7.3 (m, 2H), 7.16 (td, 1H, J=2.7, 6.4 Hz), 6.88 (d, 2H, J=7.7 Hz), 4.44
(s, 2H), 4.01 (t, 2H, J=6.4 Hz), 3.80 (s, 3H), 3.48 (t, 2H, J=6.6 Hz), 1.8-1.9 (m, 2H), 1.6-1.7 (m,
2H), 1.5-1.6 (m, 2H) ppm.
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C NMR (126 MHz, CDCl3) δ 192.2, 159.6, 159.1, 137.7, 130.6,

130.0, 129.2, 123.3, 121.9, 113.8, 112.8, 72.6, 69.8, 68.1, 55.3, 29.5, 28.9, 22.8 ppm. HRMS
m/z: [M+Na]+ calcd for C20H24O4Na 351.1567; found 351.1567.

Using conditions identical to those described above for compound 4.04, 4.13 (1.70 g, 5.18 mmol)
was converted to 4.14 to yield a tan solid (1.83 g, 95%). 1H NMR (500 MHz, CDCl3) δ 7.74 (d,
1H, J=16.1 Hz), 7.3 (m, 2H), 7.2-7.3 (m, 2H), 7.12 (d, 1H, J=7.3 Hz), 7.0-7.1 (m, 1H), 6.9-7.0
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(m, 1H), 6.9 (m, 2H), 6.43 (d, 1H, J=16.1 Hz), 4.44 (s, 2H), 3.98 (t, 2H, J=6.6 Hz), 3.80 (s, 3H),
3.48 (t, 2H, J=6.6 Hz), 1.8-1.9 (m, 2H), 1.6-1.7 (m, 2H), 1.5-1.6 (m, 2H) ppm.
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C NMR (126

MHz, CDCl3) δ 171.1, 159.4, 159.1, 146.9, 135.4, 130.6, 129.9, 129.2, 120.9, 117.4, 117.1,
113.8, 113.7, 72.6, 69.9, 67.9, 55.3, 29.5, 29.0, 22.) ppm. HRMS m/z: [M+H]+ calcd for
C22H27O5 371.1853; found 371.1853.

Using conditions identical to those described above for compound 4.05, 4.14 (2.31 g, 6.23 mmol)
was converted to 4.15 to yield a yellow oil (2.70 g, 101% [solvent]). The product was used in the
next step without further purification. 1H NMR (500 MHz, CDCl3) δ 7.79 (d, 1H, J=15.7 Hz),
7.3 (m, 1H), 7.2-7.3 (m, 3H), 7.12 (d, 1H, J=7.3 Hz), 7.0-7.1 (m, 1H), 6.97 (dd, 1H, J=2.4, 8.3
Hz), 6.8-6.9 (m, 2H), 6.40 (d, 1H, J=15.7 Hz), 4.44 (s, 2H), 4.0 (m, 2H), 3.94 (s, 3H), 3.80 (s,
3H), 3.48 (t, 2H, J=6.6 Hz), 1.8-1.9 (m, 2H), 1.6-1.7 (m, 2H), 1.5-1.6 (m, 2H) ppm.

Using conditions identical to those described above for compound 4.06, 4.15 (2.70 g, 6.30 mmol)
was converted to 4.16 to yield a yellow oil (2.43 g, 98%). The crude product was used in the next
step without further purification.
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Using conditions identical to those described above for compound 4.07, 4.16 (2.43 g, 6.14 mmol)
was attempted to be converted to 4.17. The reaction did not yield the desired product 4.17.

1,5-Pentanediol (3.07 g, 29.5 mmol) was dissolved in 140 mL of dry THF in a 500 mL round
bottomed flask in an ice water bath and containing a stir bar. NaH (60% in mineral oil, 1.30 g,
32.4 mmol) was added to the solution in portions and it was allowed to stir at 0 °C for 30 min,
then the reaction was warmed to room temperature and stirred for 2 h. TBSCl (4.35 g, 28.8
mmol) was then added to the reaction. The reaction was stirred at room temperature for 14 h to
give a white suspension. The reaction was quenched by adding water dropwise, and then the
mixture was diluted in Et2O and the organic fraction was washed repeatedly with water. The
organic layer was dried with MgSO4 and concentrated on a rotary evaporator. The residue was
purified by flash column chromatography (3:1 hexanes:ethyl acetate) to yield 4.18 (4.76 g, 76%)
as a clear oil. 1H NMR (400 MHz, CDCl3) δ 3.61 (td, 4H, J=6.4, 11.1 Hz), 1.5-1.6 (m, 4H), 1.31.4 (m, 2H), 0.8-0.9 (m, 9H), 0.0-0.1 (m, 6H) ppm.

13

C NMR (101 MHz, CDCl3) δ 63.1, 62.9,

32.5, 26.0, 22.0, 18.4, -5.) ppm. HRMS m/z: [M+H]+ calcd for C11H27O2Si 219.1775; found
219.1772.
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Using conditions identical to those described above for compound 4.02, 4.18 (3.23 g, 14.8 mmol)
was converted to 4.19 to yield a light yellow oil (4.62 g, 84%). 1H NMR (500 MHz, CDCl3) δ
7.8 (m, 2H), 7.34 (d, 2H, J=7.8 Hz), 4.02 (t, 2H, J=6.6 Hz), 3.55 (t, 2H, J=6.4 Hz), 2.44 (s, 3H),
1.6-1.7 (m, 2H), 1.45 (br dd, 2H, J=6.4, 8.3 Hz), 1.3-1.4 (m, 2H), 0.8-0.9 (m, 9H), 0.0-0.1 (m,
6H) ppm. 13C NMR (126 MHz, CDCl3) δ 144.6, 133.2, 129.8, 127.9, 70.6, 62.7, 32.0, 28.6, 25.9,
25.6, 21.8, 18.3, -5.) ppm.

Using conditions identical to those described above for compound 4.03, 4.19 (5.61 g, 15.1 mmol)
was converted to 4.20 to yield a yellow oil (2.98 g, 61%). 1H NMR (500 MHz, CDCl3) δ 9.97 (s,
1H), 7.4-7.5 (m, 2H), 7.38 (d, 1H, J=2.0 Hz), 7.16 (td, 1H, J=2.8, 6.1 Hz), 4.02 (t, 2H, J=6.6
Hz), 3.64 (t, 2H, J=6.4 Hz), 1.8-1.9 (m, 2H), 1.5-1.6 (m, 4H), 0.89 (s, 9H), 0.0-0.1 (m, 6H) ppm.
C NMR (126 MHz, CDCl3) δ 192.2, 159.7, 137.7, 130.0, 123.3, 121.9, 112.7, 68.2, 62.9, 32.5,
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28.9, 26.0, 22.3, 18.4, -5.) ppm. HRMS m/z: [M+H]+ calcd for C18H31O3Si 323.2037; found
323.2039.

Compound 4.20 (0.538 g, 1.66 mmol), malonic acid (0.700 g, 6.73 mmol), and piperidine (0.111
mL, 1.12 mmol) were added to a 100 mL round bottomed flask containing a stir bar. 7 mL of
pyridine were added, and the mixture was heated to a reflux for 6 h. Upon cooling, the reaction
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mixture was poured into a 1 L Erlenmeyer flask containing 30 mL 2 M HCl and was left to stir in
an ice water bath for 1 h. The product did not precipitate, so it was extracted with DCM and
washed with cold 1 M HCl to yield 4.21 (0.446 g, 73%) as a tan solid. 1H NMR (500 MHz,
CDCl3) δ 7.75 (d, 1H, J=15.7 Hz), 7.30 (t, 1H, J=7.6 Hz), 7.13 (d, 1H, J=7.8 Hz), 7.06 (s, 1H),
6.95 (dd, 1H, J=2.7, 8.1 Hz), 6.43 (d, 1H, J=15.7 Hz), 4.0 (m, 2H), 3.65 (t, 2H, J=6.1 Hz), 1.81.9 (m, 2H), 1.59 (br d, 2H, J=6.8 Hz), 1.5-1.6 (m, 2H), 0.90 (s, 9H), 0.0-0.1 (m, 6H) ppm. 13C
NMR (126 MHz, CDCl3) δ 159.4, 159.4, 147.0, 135.3, 129.9, 120.9, 117.3, 117.2, 113.7, 68.0,
63.0, 32.5, 29.0, 26.0, 22.3, 18.4, -5.3 ppm. HRMS m/z: [M+H]+ calcd for C20H33O4Si 365.2143;
found 365.2144.

Carboxylic acid 4.21 (0.446 g, 1.22 mmol) was placed in a 50 mL round bottomed flask
containing a stir bar. It was dissolved in 3 mL of Et2O and 1 mL of DCM (for improved
solubility), and then Et3N (0.170 mL, 1.22 mmol) was added. The flask was flushed with argon,
sealed with a rubber septum, placed in an ice water bath, and allowed to stir for 5 min. Methyl
chloroformate (0.100 mL, 1.29 mmol) was added dropwise via syringe over 5 minutes. The
reaction was stirred at 0 °C for 45 minutes, then it was quenched with 0.5 mL 0.1 M HCl. The
resulting organic layer was separated and washed with additional 0.1 M HCl solution (1x),
saturated NaHCO3 (1x), and brine (1x). The organic fractions were dried with Na2SO4 and
concentrated on a rotary evaporator to yield 4.22 (0.49 g, 95%) as a yellow oil that was used
without further purification.
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Using conditions identical to those described above for compound 4.06, 4.22 (2.15 g, 5.09 mmol)
was converted to 4.23 to yield a brown oil (1.76 g, 89%). The product was used in the next step
without further purification.

Using conditions identical to those described above for compound 4.07, 4.23 (1.76 g, 4.52 mmol)
was attempted to be converted to 4.24. The reaction did not yield the desired product 4.24.

3-Hydroxybenzaldehyde (2.00 g, 16.4 mmol), methyl iodide (1.54 mL, 24.6 mmol), and
potassium carbonate (4.56 g, 33.0 mmol) were dissolved in 80 mL of acetone in a 250 mL round
bottomed flask containing a stir bar to give a tan suspension. The mixture was stirred at room
temperature for 16 h. The solvent was evaporated and the residue was extracted with ethyl
acetate. The mixture was washed with brine, and the organic fractions were dried with Na2SO4
and concentrated on a rotary evaporator to give a brown oil. The crude residue was purified by
flash column chromatography (10- 20% ethyl acetate in hexanes) to yield 4.28 (1.90 g, 85%) as a
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clear oil. 1H NMR (500 MHz, CDCl3) δ 9.98 (s, 1H), 7.4-7.5 (m, 2H), 7.4 (m, 1H), 7.2 (m, 1H),
3.9 (m, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 192.1, 160.1, 137.8, 130.0, 123.6, 121.5, 112.0,
55.5 ppm. HRMS m/z: [M+H]+ calcd for C8H9O2 137.0597; found 137.0599.

Compound 4.28 (3.40 g, 30.0 mmol), malonic acid (10.45 g, 100 mmol), and piperidine (1.66
mL, 16.8 mmol) were added to a 250 mL round bottomed flask containing a stir bar. 80 mL of
pyridine were added, and the mixture was heated to a reflux for 6 h. Upon cooling, the reaction
mixture was poured into a 1 L Erlenmeyer flask containing 300 mL of 2 M HCl and was left to
stir in an ice water bath for 1 h. A few drops of 6 M HCl were added to promote precipitation.
The resulting precipitate was collected by vacuum filtration and washed with cold 1 M HCl to
yield 4.29 (3.38 g, 76%) as a white solid. 1H NMR (400 MHz, CDCl3) 7.75 (d, 1H, J=16.0 Hz),
7.3 (m, 1H), 7.13 (br d, 1H, J=7.6 Hz), 7.05 (br s, 1H), 6.95 (dd, 1H, J=2.0, 8.1 Hz), 6.43 (d, 1H,
J=16.0 Hz), 3.82 (s, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 172.0, 159.9, 146.9, 135.3, 129.8,
121.0, 117.4, 116.6, 113.0, 55.4 ppm.

Carboxylic acid 4.29 (2.23 g, 12.5 mmol) was placed in a 100 mL round bottomed flask
containing a stir bar. It was dissolved in 37 mL of Et2O and 5 mL of DCM (for improved
solubility), and then Et3N (1.745 mL, 12.5 mmol) was added. The flask was flushed with argon,
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sealed with a rubber septum, placed in an ice water bath, and allowed to stir for 5 min. Methyl
chloroformate (0.970 mL, 12.5 mmol) was added dropwise via syringe over 5 minutes. The
reaction was stirred at 0 °C for 1 h, then it was quenched with 0.5 mL of 0.1 M HCl. The
resulting organic layer was separated and washed with additional 0.1 M HCl solution (1x),
saturated NaHCO3 (1x), and brine (1x). The organic fractions were dried with Na2SO4 and
concentrated on a rotary evaporator to yield 4.30 (2.85 g, 96%) as a light yellow oil that was
used without further purification. 1H NMR (400 MHz, CDCl3) δ 7.78 (d, 1H, J=15.6 Hz), 7.3 (m,
1H), 7.13 (d, 1H, J=7.8 Hz), 7.0-7.1 (m, 1H), 7.0 (m, 1H), 6.39 (d, 1H, J=16.0 Hz), 3.93 (s, 3H),
3.82 (s, 3H) ppm.

Compound 4.30 (2.20 g, 9.31 mmol) was dissolved with 22 mL of dioxane in a 100 mL round
bottomed flask containing a stir bar. The reaction mixture was placed in an ice water bath. A
solution of NaN3 (0.762 g, 11.7 mmol) in 4 mL of water was added dropwise over 10 min to the
reaction mixture. The reaction was stirred with constant cooling at 0 °C for 1 h. The reaction
mixture was then poured over ice, extracted with ethyl acetate, and washed with saturated
NaHCO3. The organic layer was dried with Na2SO4 and concentrated on a rotary evaporator with
no heat to yield 4.31 (1.73 g, 91%) as a tan oil that was used without further purification.
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Compound 4.31 (2.94 g, 14.5 mmol) was dissolved in 60 mL of o-dichlorobenzene in a 100 mL
round bottomed flask containing a stir bar. The reaction mixture was heated slowly to 75 °C by
increasing by 10 °C every 20-30 minutes, and then heated at 75 °C for 3 h. Catalytic I2 (one
small crystal) was added to the reaction and then heated at 180 °C overnight. The mixture was
cooled to room temperature. The solvent was removed by high vacuum distillation at 90 °C to
give a brown residue. The crude residue was purified by flash column chromatography (40%
ethyl acetate in hexanes - 100% ethyl acetate) to yield 4.32 (1.32 g, 52%) as a tan solid. 1H NMR
(400 MHz, CDCl3) 10.63 (br s, 1H), 8.31 (d, 1H, J=8.9 Hz), 7.0-7.1 (m, 2H), 6.89 (d, 1H, J=2.2
Hz), 6.45 (d, 1H, J=7.1 Hz), 3.90 (s, 3H) ppm.

C NMR (126 MHz, CDCl3) δ 163.8, 163.0,
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140.3, 129.3, 128.3, 119.9, 116.4, 106.9, 106.4, 55.5 ppm. LRMS m/z: [M+H]+ = 176. HRMS
m/z: [M+H]+ calcd for C10H10NO2 176.0706; found 176.0708.

Compound 4.32 (1.22 g, 6.94 mmol) was suspended in 12 mL of 6 M HCl in a 30 mL
microwave vial. The reaction mixture was irradiated in the microwave reactor at 180 °C for 40
min. The acid was neutralized with freshly prepared 2 M NaOH solution to a pH of 7. Any
remaining starting material was extracted with ethyl acetate. The aqueous layer was concentrated
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on a rotary evaporator with heat to yield a mixture of product and NaCl. The residue was
dissolved in methanol and filtered; the filtrate was then concentrated on a rotary evaporator and
the procedure was repeated until most of the salt was removed to yield 4.27 (1.16 g, 70-100%
[contains NaCl]) as a tan solid. 1H NMR (CD3OD , 400 MHz) δ 8.14 (d, 1H, J=8.8 Hz), 7.09 (d,
1H, J=7.0 Hz), 6.98 (br dd, 1H, J=2.0, 8.7 Hz), 6.9 (m, 1H), 6.55 (br d, 1H, J=7.1 Hz) ppm.
LRMS m/z: [M+H]+ = 162. HRMS m/z: [M+H]+ calcd for C9H8NO2 162.0550; found 162.0557.

Compound 4.18 (1.01 g, 4.62 mmol), 4-hydroxybenzonitrile (0.456 g, 3.83 mmol), and
triphenylphosphine (1.51 g, 5.74 mmol) were dissolved in 30 mL of dry THF in a 100 mL round
bottomed flask containing a stir bar. The reaction mixture was placed in an ice water bath to
maintain the temperature at 0 °C. DIAD (1.15 mL, 5.91 mmol) was added dropwise to the
reaction mixture with constant stirring. The solution warmed to room temperature and stir for 16
hours. The solvent was removed on a rotary evaporator, and the residue was purified by flash
column chromatography (5-15% ethyl acetate in hexanes) to yield 4.33 (1.14 g, 93%) as a cloudy
white oil. 1H NMR (500 MHz, CDCl3) δ 7.56 (d, 2H, J=8.2 Hz), 6.92 (d, 2H, J=8.3 Hz), 4.00 (t,
2H, J=6.5 Hz), 3.63 (t, 2H, J=6.2 Hz), 1.8-1.9 (m, 2H), 1.5-1.6 (m, 4H), 0.89 (s, 9H), 0.0-0.1 (m,
6H) ppm.

13

C NMR (126 MHz, CDCl3) δ 162.4, 133.9, 119.3, 115.1, 103.6, 68.3, 62.9, 32.4,

28.8, 25.9, 22.3, 18.3, -5.3 ppm. HRMS m/z: [M+Na]+ calcd for C18H29NNaO2Si 342.1860;
found 342.1874.
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Compound 4.33 (1.99 g, 6.24 mmol) was dissolved in 11 mL of THF in a 100 mL round
bottomed flask containing a stir bar. A solution of 1 M TBAF in THF (9.36 mL, 9.36 mmol) was
added to the reaction mixture and it was stirred at room temperature for 1 day. The mixture was
diluted in water and was extracted with Et2O (3x) and the combined organic extracts were
washed with saturated NH4Cl. The organic layer was dried with MgSO4 and concentrated on a
rotary evaporator. The residue was purified by flash column chromatography (20 -60% ethyl
acetate in hexanes) to yield 4.34 (1.16 g, 91%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.55
(br d, 2H, J=8.7 Hz), 6.91 (br d, 2H, J=8.7 Hz), 3.99 (t, 2H, J=6.3 Hz), 3.6-3.7 (m, 2H), 1.83
(quin, 2H, J=6.9 Hz), 1.5-1.7 (m, 4H), 1.28 (br s, 1H) ppm.
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C NMR (101 MHz, CDCl3) δ

162.3, 133.9, 119.2, 115.1, 103.7, 68.2, 62.7, 32.3, 28.7, 28.7, 22.3 ppm. HRMS m/z: [M+H]+
calcd for C12H16NO2 206.1176; found 206.1176.

Compound 4.34 (0.610 g, 2.97 mmol) was dissolved in 10 mL of DCM in a 100 mL round
bottomed flask containing a stir bar. Et3N (0.621 mL, 4.46 mmol), tosyl chloride (0.627 g, 3.29
mmol), and DMAP (0.0191 g, 0.156 mmol) were added to the reaction mixture and it was stirred
at room temperature for 16 h. The reaction mixture was diluted in DCM, and it was then washed
with aqueous NaHCO3 (1x), water (1x), and brine (1x). The organic fractions were dried with
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MgSO4 and concentrated on a rotary evaporator. The residue was purified by flash column
chromatography (15% ethyl acetate in hexanes) to yield 4.26 (0.688 g, 64%) as a white solid. 1H
NMR (500 MHz, CDCl3) 7.79 (d, 2H, J=8.3 Hz), 7.57 (d, 2H, J=8.3 Hz), 7.34 (d, 2H, J=8.0 Hz),
6.90 (d, 2H, J=8.3 Hz), 4.06 (t, 2H, J=6.3 Hz), 3.96 (t, 2H, J=6.3 Hz), 2.44 (s, 3H), 1.7-1.8 (m,
4H), 1.5-1.5 (m, 2H) ppm.
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C NMR (126 MHz, CDCl3) δ 162.2, 144.8, 134.0, 133.1, 129.8,

127.8, 119.2, 115.1, 103.8, 70.2, 67.9, 28.6, 28.3, 22.1, 21.6 ppm. HRMS m/z: [M+H]+ calcd for
C19H22NO4S 360.1264; found 360.1258.

Compound 4.26 (0.477 g, 1.33 mmol), 4.27 (0.792 g, 4.91 mmol), and potassium carbonate
(0.282 g, 2.04 mmol) were added to a 25 mL round bottomed flask containing a stir bar and the
mixture was dissolved in 6 mL of acetonitrile. The reaction mixture was heated to 90 °C for 3.5
h to form a tan suspension. Upon cooling, the solvent was removed on a rotary evaporator and
the residue was extracted with dichloromethane (2x) and washed with water. Unreacted 4.27 was
collected from the aqueous layer by the methods described above. The organic layer was dried
with Na2SO4 and concentrated on a rotary evaporator. The residue was purified by flash column
chromatography (40% ethyl acetate in hexanes - 100% ethyl acetate) to yield 4.25 (0.117 g,
25%) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.9-11.1 (m, 1H), 8.04 (d, 1H,
J=8.9 Hz), 7.7-7.8 (m, 2H), 7.0-7.1 (m, 4H), 7.01 (dd, 1H, J=2.4, 8.9 Hz), 6.43 (d, 1H, J=7.0
Hz), 4.08 (dt, 4H, J=3.9, 6.4 Hz), 1.7-1.9 (m, 4H), 1.5-1.7 (m, 2H) ppm.

13

C NMR (DMSO-d6,

126 MHz) δ 162.6, 162.0, 162.0, 140.5, 134.6, 129.9, 129.1, 120.2, 116.4, 116.0, 108.1, 104.9,
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103.1, 68.4, 68.1, 31.4, 28.7, 28.6, 22.5 ppm. HRMS m/z: [M+H]+ calcd for C21H21N2O3
349.1547; found 349.1579.

Compound 4.32 (0.0989 g, 0.565 mmol) and neat phosphorus oxychloride (2.63 mL, 28.2 mmol)
were added to a 25 mL round bottomed flask containing a stir bar. The reaction mixture was
heated at 120 °C for 3 h. The mixture was cooled and the POCl3 was removed on a rotary
evaporator with heat. The residue was extracted with dichloromethane and washed with brine.
The organic layer was dried with Na2SO4 and concentrated on a rotary evaporator to yield 4.35
(0.105 g, 96%) as a brown solid, which was used without further purification. 1H NMR (500
MHz, CDCl3) δ 8.25 (d, 1H, J=9.2 Hz), 8.21 (d, 1H, J=5.8 Hz), 7.54 (d, 1H, J=5.7 Hz), 7.33 (dd,
1H, J=2.5, 9.3 Hz), 7.11 (d, 1H, J=2.4 Hz), 3.98 (s, 3H) ppm.
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C NMR (151 MHz, CDCl3) δ

161.7, 151.1, 142.0, 140.0, 128.3, 122.4, 121.3, 120.1, 104.7, 55.7 ppm. HRMS m/z: [M+H]+
calcd for C10H9ClNO 194.0367; found 194.0381.

Compound 4.35 (0.030 g, 0.155 mmol) and neat benzylamine (0.085 mL, 0.78 mmol) were
added to a 10 mL round bottomed flask containing a stir bar. The reaction mixture was heated at
200 °C for 2 h. The mixture was cooled and the benzylamine was removed on a rotary
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evaporator with heat. The residue was purified by flash column chromatography (25% ethyl
acetate in hexanes) to yield 4.36 (0.0156 g, 38%) as a tan oil. HRMS m/z: [M+H]+ calcd for
C17H17N2O 265.1335; found 265.1363.

Compound 4.36 (15 mg, 0.057 mmol) was dissolved in 3 mL of methanol in a 10 mL screw-cap
reaction vial containing a stir bar. Catalytic 10% w/w palladium on carbon (15.8 mg, 7.42 µmol)
and ammonium formate (29 mg, 0.46 mmol) were added to the reaction mixture. The reaction
vial was sealed and heated at 70 °C for 7 days. The reaction was incomplete, but LRMS showed
the formation of product with an [M+H]+ of 175. The reaction mixture was filtered through celite
and rinsed with methanol. The filtrate was concentrated and the residue was purified by flash
column chromatography (90% DCM, 10% of a 10% ammonium hydroxide in methanol solution)
to yield 4.37 (8 mg, 8%) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 8.1-8.2 (m, 2H), 7.42 (br
d, 1H, J=6.7 Hz), 7.0-7.0 (m, 1H), 6.87 (br d, 1H, J=6.7 Hz), 3.94 (s, 3H), 3.6-3.7 (m, 1H), 3.33
(s, 1H) ppm. HRMS m/z: [M+H]+ calcd for C10H11N2O 175.0866; found 175.0876.

4-Bromobenzonitrile (0.300 g, 1.65 mmol) and ammonium chloride (0.359 g, 6.70 mmol) were
added to a 10 mL Fisher culture tube with a phenolic screw cap with rubber liner. It was placed
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in a dry ice bath at -78 °C, and then 2 mL of liquid ammonia were added as solvent. The vial was
sealed and warmed to room temperature while checking for leaks. The reaction was heated at 60
°C overnight. The reaction was cooled to room temperature, then further cooled to -78 °C and
the reaction was vented. The mixture was allowed to warm to room temperature to allow for the
ammonia to evaporate. The residue was diluted in dichloromethane and washed with 0.1 M
NaOH. The organic layer was dried with Na2SO4 and concentrated on a rotary evaporator to
yield 4.38 (0.209 g, 64%) as a white solid that did not require further purification. 1H NMR (400
MHz, CD3OD) δ 7.7-7.8 (m, 2H), 7.6-7.7 (m, 2H), 3.32 (s, 1H) ppm.
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C NMR (101 MHz,

CD3OD) δ 133.4, 132.4, 127.5, 111.0 ppm. LRMS m/z: [M+H]+ = 199/201.

Compound 4.25 (0.373 g, 1.07 mmol) and neat phosphorus oxychloride (4.0 mL, 42.9 mmol)
were added to a 25 mL round bottomed flask containing a stir bar. The reaction mixture was
heated at 120 °C for 3 h. The mixture was cooled and the POCl3 was removed on a rotary
evaporator with heat. The residue was extracted with dichloromethane and washed with brine.
The organic extract was dried with Na2SO4 and concentrated on a rotary evaporator to a brown
tar. The residue was purified by flash column chromatography (40% ethyl acetate in hexanes –
100% ethyl acetate) to yield 4.39 (0.316 g, 80%) as an off-white solid. 1H NMR (600 MHz,
CDCl3) δ 8.1-8.2 (m, 2H), 7.55 (d, 2H, J=8.7 Hz), 7.43 (d, 1H, J=5.6 Hz), 7.25 (dd, 1H, J=2.3,
9.3 Hz), 7.04 (d, 1H, J=2.2 Hz), 6.91 (d, 2H, J=8.7 Hz), 4.12 (t, 2H, J=6.3 Hz), 4.03 (t, 2H,
J=6.3 Hz), 1.9-2.0 (m, 4H), 1.7-1.7 (m, 2H) ppm. 13C NMR (151 MHz, CDCl3) δ 162.2, 160.9,
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151.1, 142.1, 139.8, 133.9, 128.3, 128.3, 121.4, 120.0, 119.2, 115.1, 105.3, 68.1, 68.0, 28.7, 22.7
ppm. HRMS m/z: [M+H]+ calcd for C21H20ClN2O2 367.1208; found 367.1244.

Compound 4.39 (59 mg, 0.16 mmol) and neat benzylamine (0.300 mL, 2.75 mmol) were added
to a 10 mL round bottomed flask containing a stir bar. The reaction mixture was heated at 200 °C
for 2 h. The mixture was cooled and the benzylamine was removed on a rotary evaporator with
heat. The residue was purified by flash column chromatography (30% ethyl acetate in hexanes)
to yield 4.40 (51.1 mg, 73%) as a tan solid. 1H NMR (400 MHz, CDCl3) 7.95 (d, 1H, J=5.9 Hz),
7.68 (d, 1H, J=9.1 Hz), 7.55 (d, 2H, J=8.8 Hz), 7.42 (br d, 2H, J=7.2 Hz), 7.3-7.4 (m, 3H), 7.07.1 (m, 1H), 6.8-7.0 (m, 4H), 5.49 (br s, 1H), 4.80 (br d, 2H, J=3.7 Hz), 4.09 (t, 2H, J=6.3 Hz),
4.03 (t, 2H, J=6.3 Hz), 1.8-2.0 (m, 4H), 1.6-1.8 (m, 2H) ppm.
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C NMR (101 MHz, CDCl3) δ

162.3, 159.9, 154.7, 141.6, 139.4, 139.1, 134.0, 128.7, 128.0, 127.4, 123.4, 119.3, 117.8, 115.1,
112.9, 111.0, 106.4, 103.7, 68.1, 67.8, 46.0, 28.8, 28.7, 22.7 ppm. HRMS m/z: [M+Na]+ calcd
for C28H27N3NaO2 460.1995; found 460.2030.
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Compound 4.40 (51.0 mg, 0.117 mmol) and ammonium chloride (30.7 mg, 0.574 mmol) were
dissolved in 2 mL of methanol and added to a 10 mL Fisher culture tube with a phenolic screw
cap with rubber liner. It was placed in a dry ice bath at -78 °C, and then 2 mL of liquid ammonia
was added as solvent. The vial was sealed and warmed to room temperature while checking for
leaks. The reaction was heated to 130 °C over the course of 7 days, starting at 60 °C and
increasing by 10 °C each day while monitoring reaction progression every two days. The
reaction was cooled to room temperature, then further cooled to -78 °C and the reaction was
vented. The mixture was allowed to warm to room temperature to allow for the ammonia to
evaporate. The residue was diluted in dichloromethane and washed with 0.1 M NaOH. The
organic layer was dried with Na2SO4 and concentrated on a rotary evaporator. The residue was
purified by flash column chromatography (30% ethyl acetate in hexanes → 100% ethyl acetate
→ 88% ethyl acetate, 12% of a 10% ammonium hydroxide in methanol solution) to yield 4.41
(2.1 mg, 4%) as a tan solid. LRMS m/z: [M+2H]2+/2 = 228. Other byproducts were isolated from
this reaction, such as 4.39 and 4.44. For 4.44: HRMS m/z: [M+H]+ calcd for C22H23N2O3
363.1703; found 363.1752. For 4.43: 1H NMR (400 MHz, CDCl3) δ 7.97 (br s, 1H), 7.73 (br d,
1H, J=8.2 Hz), 7.5-7.6 (m, 2H), 7.3-7.4 (m, 1H), 7.2-7.3 (m, 1H), 7.14 (br s, 1H), 6.8-7.0 (m,
3H), 5.09 (s, 1H), 3.9-4.2 (m, 4H), 3.33 (s, 2H), 1.8-1.9 (m, 4H), 1.68 (br d, 1H, J=6.6 Hz) ppm.
LRMS m/z: [M+2H]2+/2 = 182.9. HRMS m/z: [M+H]+ calcd for C21H25N4O2 365.1972; found
365.1937.
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Compound 4.39 (0.3164 g, 0.862 mmol) and ammonium chloride (0.2035 g, 3.80 mmol) were
added to a 10 mL Fisher culture tube with a phenolic screw cap with rubber liner. It was placed
in a dry ice bath at -78 °C, and then 5 mL of liquid ammonia was added as solvent. The vial was
sealed and warmed to room temperature while checking for leaks. The reaction was heated to
130 °C slowly over the course of a few hours. The reaction was cooled to room temperature, then
further cooled to -78 °C and the reaction was vented. The mixture was warmed to room
temperature to allow for the ammonia to evaporate. The residue was diluted in dichloromethane
and washed with 0.1 M NaOH. The organic layer was dried with Na2SO4 and concentrated on a
rotary evaporator.
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Appendix I
Biological Assays
Chapter 2
1. Cell Culture
HeLa, M17, and HEK293T cells were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% fetal bovine serum (FBS) as previously described; for all hormone
treatments, charcoal-stripped FBS was used instead for at least 16 h before treatment started. For
the high-throughput screen, HeLa cells were transfected in suspension with 200 ng of the GRE
luciferase reporter and FKBP51 or 6/TR (six repeats of the tetracycline repressor sequence) as a
control using 3 μL/μg of Mirus TransIT2020 transfection reagent (Mirus Bio, Madison, WI) in
serum-free media and plated in 96-well plates. Cells were treated 24 h later with hydrocortisone
(50 nm; Sigma-Aldrich) and compounds from the LOPAC 1280 drug library (Sigma-Aldich, St.
Louis, MO) in triplicate wells at 10 μM. Cells were harvested 16 h later in Cell Culture Lysis
Reagent (Promega, Madison, WI) and transferred to opaque, white polystyrene 96-well plates.
Luciferase assays were performed with the Luciferase Assay System (Promega) according to the
manufacturer’s protocols, and luminescence was immediately read on a multimodal plate reader
(Biotek Synergy H1, Biotek, Winooski, VT).
2. Expression, Purification, and Labeling of Recombinant Proteins
FKBP51, FKBP52, and Hsp90α proteins were generated as described. Briefly, full-length wildtype human FKBP51, FKBP52, or Hsp90α was cloned into a pET28 vector, expressed in E. coli,
and purified via Ni-NTA-agarose chromatography followed by size exclusion chromatography.
Protein purity was verified by Coomassie blue SDS-PAGE. Purified proteins were labeled for
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flow cytometric protein−protein interaction evaluation as previously described. Recombinant
GR-LBD was incubated with biotin for 1 h followed by washes to remove excess biotin. The
biotin-labeled protein was then immobilized with streptavidin coated polystyrene particles
(Spherotech, Lake Forest, IL) for 1 h followed by washes to remove any unbound protein. For
the experiment using biotinylated benztropine, we used the Dynabeads M-280 Streptavidin
particles (Thermo Fisher Scientific, #11205D) that have a smaller diameter and a strong binding
affinity for biotin allowing better drug−protein interaction. FKBP51, FKBP52, and BSA were
chemically labeled with Alexafluor 488 carboxylic acid succinimidyl ester (Life Technologies)
following the manufacturer’s protocol.
3. Flow Cytometry Protein Interaction Assay
For the drug binding and complex interaction experiment, biotinylated GR-LBD and Alexafluor
488 conjugated FKBP51 were incubated together, with Hsp90α to facilitate the interaction, in
equimolar ratios for 30 min with varying concentrations of drug. For the benztropine specificity
assay, Dynabeads Streptavidin particles were washed three times with BSA/PBS (0.2 mg mL−1).
The streptavidin particles were then incubated for 30 min with recombinant fluorescently labeled
FKBP51, FKBP52, or BSA in the presence or absence of a biotinylated-benztropine. All
conditions were run in triplicate on separate days. Binding was evaluated using an Accuri C6
flow cytometer (BD Biosciences, San Jose, CA) to quantify median bead-associated
fluorescence. Background scatter and fluorescence were subtracted from the signal.
4. Co-Immunoprecipitation
Briefly, HeLa cells were transfected with 3 μg of FKBP51 and treated overnight with
hydrocortisone (50 nm) and benztropine (10 μM). Cells were harvested in M-PER buffer, and
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lysates were incubated overnight in rabbit anti-GR antibody (Cell Signaling) at 4 °C. Magnetic
protein A beads (Life Technologies) were incubated with samples for 4 h at 4 °C, followed by
five washes and a denaturing elution. The resulting precipitates were subjected to SDS-PAGE.
5. SDS-PAGE
Membranes were incubated overnight with primary antibodies directed against rabbit GR
(1:1000; Cell Signaling), mouse GAPDH (1:5000; Meridian Life Sciences, Mempthis, TN),
rabbit histone H3 (1:1000; Abcam, Cambridge, MA), or goat Lamin B (1:500; Santa Cruz,
Dallas, TX). Chemiluminescence was detected with an ImageQuant LAS 4000 imaging system
(GE Life Sciences, Pittsburgh, PA), and band densitometry was analyzed using Scion Image. All
samples were run in duplicate and normalized to GAPDH for cytosolic fractions or Histone H3
or Lamin B for nuclear fractions prior to analysis
6. Primary Neuronal Cultures
Primary cortical neurons were isolated from E16.5 wild-type mouse brains using previous
established protocols. Briefly, brains were extracted, meninges were removed, and cortices were
placed in ice-cold isotonic buffer (137 mM NaCl, 5 mM KCl, 0.2 mM NaH2PO4, 0.2 mM
KH2PO4, 5.5 mM glucose, and 6 mM sucrose, pH 7.4). Following washes, cortices were
minced, digested in trypsin, triturated, and resuspended in DMEM supplemented with 10% FBS,
penicillin/streptomycin, and Amphotericin B. The DMEM was exchanged 24 h later for
Neurobasal medium supplemented with Glutamax and B27 supplement (Life Technologies).
Primary neurons were transduced at DIV4 with 2 μL/ well of eGFP or FKBP51 AAV in PBS at
1013 viral particles per microliter. At DIV14, neurons were treated with dexamethasone (0.5
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μM) and/or benztropine (10 μM) for 3 h prior to harvesting using subcellular fractionation to
isolate cytosolic and nuclear fractions as described above.
7. Statistical Analyses
Statistical significance for each analysis was determined with Student’s t-tests or one- or twoway analysis of variance (ANOVA) with Tukey or Bonferroni post-tests to compare groups. All
figures and statistics were generated using GraphPad Prism software; each graph represents the
mean ± the standard error of the mean (SEM). For analysis of the compound library screen,
luciferase values were normalized on each plate to two separate values: hormone-induced GR
activity and FKBP51 + hormone GR activity. Using SPPS statistical software, standardized
residuals were calculated from the normalized FKBP51-hormone values with hormone alone
values used as a covariate. Z scores were generated. Significance was determined by SPPS with
p < 0.0001 used as a criterion.
Chapter 3
1. Cell culture
Tetracycline-regulatable P301L 4R0N tau stably expressing HEK293T cells were maintained in
DMEM (Corning) plus 10% FBS (VWR Seradigm), and 1% penicillin/streptomycin
(Invitrogen). Cells were induced with tetracycline hydrochloride (Sigma-Aldrich) for 24 hours,
then treated with compounds at 1µM, 3µM, 1µM, and 10µM respectively for 24 hours. Cells
were harvested in RIPA buffer (150mM sodium chloride, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 50mM Tris [pH 8]) containing protease and phosphatase inhibitor
cocktails.
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2. Western Blotting
Following cell lysis, protein concentrations were normalized via bicinchonic acid assay (BCA;
ThermoFisher). Samples were run on 5-20% gradient SDS-PAGE gels (Biorad) then transferred
to PVDF membranes (Immunobilon, EMD Millipore). The membranes were then blocked with
7% nonfat dry milk diluted in 1x TBS for 1 hour prior to being probed overnight at 4˚C against
the primary antibody. The primary antibodies were then detected by species specific secondary
antibodies (Southern Biotech) and chemiluminescence was observed using an ECL western blot
detection reagent (GE Healthcare). The blots were quantified with ImageJ software (NIH) used
to calculate densitometry. Values shown represent percent vehicle following normalization to
GAPDH (+/- SEM).
3. Cytotoxicity
Human bone marrow neuroblastoma cells (SHSY-5Y) were maintained in Advanced
DMEM/F12 (Life Technologies) with 10% FBS (VWR Seradigm). Cells were plated onto 12well plates at 80% confluency then treated with compounds at 1µM, 3µM, 1µM, and 10µM
respectively for 24 hours. The medium was then removed in order to perform LDH cytotoxicity
assays.
4. Ex vivo slices
All procedures involving experimentation on animal subjects were done in accordance with the
guidelines set forth by the Institutional Animal Care and Use Committee of the University of
South Florida. rTg4510 transgenic mice overexpressing human 4R0N tau were decapitated and
their brains were quickly removed and sliced into 400µm coronal sections using a
vibratome. Slices recovered for 10 minutes at room temperature in a 1:1 mixture of cutting
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solution (110 mM sucrose, 60 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 5
mM glucose, 0.6 mM ascorbate, 0.5 mM CaCl2, and 7 mM MgCl2) and artificial cerebral spinal
fluid (ACSF; 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 25 mM
glucose, 2 mM CaCl2 and 1 mM MgCl2). Slices were then moved in duplicate into an
oxygenated multi-well plate at 32°C containing ACSF and treated with JG-98, AL-61, AL-69,
and AL-70 at 3 and 10µM for 6 hours. After treatment, the brain slices were homogenized in
RIPA and processed for Western blot.
5. ATPase Activity
The malachite green assay was performed as indicated in Chang, L., Bertelsen, E. B., Wisen, S.,
Larsen, E. M., Zuiderweg, E. R., and Gestwicki, J. E. (2008) High-throughput screen for small
molecules that modulate the ATPase activity of the molecular chaperone DnaK, Anal. Biochem.
372, 167-176.
6. Thioflavin T Aggregation Kinetics Assay
Tau aggregation was monitored with Thioflavin T dye. Recombinant human P301L tau was
dialyzed into 100mM sodium acetate buffer pH 7 overnight. Samples consisting of 10uM P301L
tau, 10uM heparin (MP Biomedicals), 10uM thioflavin T (Sigma), the compounds at indicated
concentrations or DMSO, and 2mM diothiothreitol (Fisher Scientific) were diluted with 100mM
sodium acetate pH 7 then loaded onto a 96-well black sided clear bottom plate (Corning costar).
A total of 200uL was added to each well. Each plate was incubated at 37 °C, and fluorescent
intensity (440 emission, 490 excitation) was measured over a 72-hour period, with readings
taken every 10 minutes using a BioTek Synergy H1 microplate reader. The endpoint Thioflavin
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T relative fluorescent units are presented and are normalized percentages of P301L tau with
DMSO vehicle.
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Chapter 3 NMR Spectra
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